ac.qq.com200.html,Document

最新推荐文章于 2022-12-23 11:59:55 发布

玩加电竞

最新推荐文章于 2022-12-23 11:59:55 发布

阅读量9.3w

点赞数

文章标签： ac.qq.com200.html

0001396814-20-000006.txt : 20200220

0001396814-20-000006.hdr.sgml : 20200220

20200220080518

ACCESSION NUMBER:0001396814-20-000006

CONFORMED SUBMISSION TYPE:8-K

PUBLIC DOCUMENT COUNT:16

CONFORMED PERIOD OF REPORT:20200220

ITEM INFORMATION:Results of Operations and Financial Condition

ITEM INFORMATION:Financial Statements and Exhibits

FILED AS OF DATE:20200220

DATE AS OF CHANGE:20200220

FILER:

COMPANY DATA:

COMPANY CONFORMED NAME:Pacira BioSciences, Inc.

CENTRAL INDEX KEY:0001396814

STANDARD INDUSTRIAL CLASSIFICATION:PHARMACEUTICAL PREPARATIONS [2834]

IRS NUMBER:510619477

STATE OF INCORPORATION:DE

FISCAL YEAR END:1231

FILING VALUES:

FORM TYPE:8-K

SEC ACT:1934 Act

SEC FILE NUMBER:001-35060

FILM NUMBER:20632586

BUSINESS ADDRESS:

STREET 1:5 SYLVAN WAY

STREET 2:SUITE 300

CITY:PARSIPPANY

STATE:NJ

ZIP:07054

BUSINESS PHONE:973-254-3560

MAIL ADDRESS:

STREET 1:5 SYLVAN WAY

STREET 2:SUITE 300

CITY:PARSIPPANY

STATE:NJ

ZIP:07054

FORMER COMPANY:

FORMER CONFORMED NAME:Pacira Pharmaceuticals, Inc.

DATE OF NAME CHANGE:20101029

FORMER COMPANY:

FORMER CONFORMED NAME:PACIRA INC

DATE OF NAME CHANGE:20080318

FORMER COMPANY:

FORMER CONFORMED NAME:Blue Acquisition Corp

DATE OF NAME CHANGE:20070418

8-K

pcrx-12312019x8xk.htm

8-K

Document

false00013968140001396814

2020-02-20

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):February 20, 2020

PACIRA BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

Delaware001-3506051-0619477

(State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.)

5 Sylvan Way, Suite 300

Parsippany,New Jersey07054

(Address and Zip Code of Principal Executive Offices)

(973)254-3560

(Registrant’s Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading symbolName of each exchange

on which registered

Common Stock, par value $0.001 per sharePCRXNasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐

Item 2.02. Results of Operations and Financial Condition.

OnFebruary 20, 2020, Pacira BioSciences, Inc. issued a press release announcing its results for thefourthquarter and full-year endedDecember 31, 2019. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 2.02 of Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

Exhibit

NumberDescription

104Cover Page Interactive Data File (Formatted as Inline XBRL)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PACIRA BIOSCIENCES, INC.

(REGISTRANT)

Dated:February 20, 2020By:/s/ KRISTEN WILLIAMS

Kristen Williams

Chief Administrative Officer and Secretary

EX-99.1

pcrx-123119x991.htm

EXHIBIT 99.1

Exhibit

NEWS RELEASE

FOR IMMEDIATE RELEASE

Pacira Reports Record Fourth Quarter and Full-Year Revenues

— Full-year 2019 revenue increases 25 percent to $421 million versus 2018 —

— Total 2020 revenue guidance of between $485 million and $500 million —

— Anesthesia-driven regional approaches are expanding and driving strong EXPAREL growth —

— Conference call today at 8:30 a.m. ET —

PARSIPPANY, N.J.,February 20, 2020- Pacira BioSciences, Inc.(Nasdaq: PCRX) today reported financial results for the fourth quarter and full-year of 2019 and provided 2020 financial guidance.

“By every measure, 2019 was an outstanding year for Pacira. We are delighted to report record revenues for EXPAREL®with our sixth consecutive quarter of more than 20 percent growth,” said Dave Stack, chairman and chief executive officer of Pacira BioSciences. “Demand has continued to mount within the anesthesia community as EXPAREL-based nerve and field blocks take hold as institutional protocol. Additionally, we enhanced our non-opioid pain management product portfolio with the addition of iovera°®and we are seeing great interest from the marketplace around this innovative system.”

“Looking forward, we intend to capitalize on this momentum with robust topline growth that will drive substantial operating leverage and cash flow, providing significant financial flexibility to invest in future growth opportunities. Our mission for 2020 remains steadfast as we continue to propel our global leadership in non-opioid pain management and deliver multiple milestones, including the publication of new data in C-section, label-expansion initiatives for pediatrics and lower extremity nerve block, and the advancement of regulatory activities in Europe, Canada, and China,” added Mr. Stack.

2019 Full-Year and Fourth Quarter Financial Highlights•Full-year revenues of$421.0 millionand fourth quarter revenues of$122.4 million.•Full-year EXPAREL®(bupivacaine liposome injectable suspension) net product sales of$407.9 millionand fourth quarter EXPAREL net product sales of$116.9 million.•Full-year iovera° net product sales were$7.9 millionand fourth quarter iovera° net product sales of$3.2 million. Pacira began recognizing sales of iovera° in April 2019 after completing its acquisition of MyoScience, Inc., a privately held medical technology company.•Full-year GAAP net loss of$11.0 millionor$0.27per share (basic and diluted).•Full-year non-GAAP net income of$70.7 millionor$1.67per diluted share.•Fourth quarter GAAP net loss of$4.9 millionor$0.12per share (basic and diluted).•Fourth quarter non-GAAP net income of$23.8 millionor$0.56per diluted share.

Recent Highlights

•Launch of national regional anesthesia training initiative with Envision Physician Services.

In January 2020, Pacira announced a collaboration with Envision Physician Services to train anesthesiology clinicians on ultrasound-guided regional anesthesia techniques utilizing long-acting local anesthetics like EXPAREL via a series of interactive workshops held across the country. The program supports the ongoing efforts by both organizations to advance the delivery of high-quality, patient-centered care.

•EXPAREL achieves primary and key secondary endpoints in Phase 4 CHOICE study in cesarean section patients.In January 2020, Pacira announced that its Phase 4 study of EXPAREL in patients undergoing Cesarean section achieved its primary endpoint with a statistically significant reduction in total postsurgical opioid consumption while maintaining pain scores through 72 hours (P≤0.001). EXPAREL demonstrated statistical significance for the key secondary endpoint of a reduction in the incidence and severity of itching for 72 hours after surgery (P≤0.05). Full study results will be submitted for publication in the peer-reviewed medical literature later this year.

•Phase 3 PLAY study of EXPAREL in pediatric patients achieves positive results.In December 2019, Pacira announced positive results from its Phase 3 PLAY study of EXPAREL administered as a single-dose infiltration in pediatric patients undergoing spinal or cardiac surgeries. Overall findings were consistent with the pharmacokinetic and safety profiles for adult patients with no safety concerns identified at a dose of 4 mg/kg. These results will provide the foundation for the company’s supplemental New Drug Application submission in the first half of 2020 to the U.S. Food and Drug Administration (FDA) seeking expansion of the EXPAREL label to include children aged six and over.

Fourth Quarter2019Financial Results•Total revenues were$122.4 millionin thefourthquarter of2019, a29%increase over the$95.1 millionreported for thefourthquarter of2018.•EXPAREL net product sales were$116.9 millionin thefourthquarter of2019, a24%increase over the$94.4 millionreported for thefourthquarter of2018.•Fourth quarter iovera° net product sales were$3.2 million. Pacira began recognizing sales of iovera° in April 2019 after completing its acquisition of MyoScience, Inc., a privately held medical technology company.•Sales of bupivacaine liposome injectable suspension to a third-party licensee for use in veterinary practice were$1.7 millionin thefourthquarter of2019, compared to$0.3 millionin2018.•Fourth quarter royalty revenue was$0.6 millioncompared to$0.4 millionin2018.•Total operating expenses were$120.7 millionin thefourthquarter of2019, compared to$82.9 millionin thefourthquarter of2018.•Research and development (R&D) expenses were$19.7 millionin thefourthquarter of2019, compared to$14.2 millionin thefourthquarter of2018. The company’s R&D expenses include $8.7 million and $6.5 million of product development and manufacturing capacity expansion costs in the fourth quarters of2019and2018, respectively.•Selling, general and administrative (SG&A) expenses were$54.2 millionin thefourthquarter of2019, compared to$44.6 millionin thefourthquarter of2018.

•GAAP net loss was$4.9 million, or$0.12per share (basic and diluted) in thefourthquarter of2019, compared to GAAP net income of$8.3 million, or$0.20per share (basic and diluted), in thefourthquarter of2018.•Non-GAAP net income was$23.8 million, or$0.57per share (basic) and$0.56per share (diluted), in thefourthquarter of2019, compared to non-GAAP net income of$19.8 million, or$0.48per share (basic) and$0.47per share (diluted), in thefourthquarter of2018.•Pacira had41.8 millionbasic weighted average shares of common stock outstanding in thefourthquarter of2019.•For non-GAAP measures, Pacira had42.6 milliondiluted weighted average shares of common stock outstanding in thefourthquarter of2019.

Full-Year2019Financial Results•Total revenues were$421.0 millionin2019, a25%increase over the$337.3 millionreported in2018.•EXPAREL net product sales were$407.9 millionin2019, a23%increase over the$331.1 millionreported in2018.•Full-year iovera° net product sales were$7.9 million. Pacira began recognizing sales of iovera° in April 2019 after completing its acquisition of MyoScience, Inc., a privately held medical technology company.•Sales of bupivacaine liposome injectable suspension to a third-party licensee for use in veterinary practice were$3.2 millionin2019, compared to$1.3 millionin2018.•Full-year royalty revenue was$2.1 millioncompared to$1.9 millionin2018.•Total operating expenses were$410.5 millionin2019, compared to$321.4 millionin2018.•Research and development (R&D) expenses were$72.1 millionin2019, compared to$55.7 millionin2018. The company’s R&D expenses include $29.7 million and $28.5 million of product development and manufacturing capacity expansion costs in2019and2018, respectively.•Selling, general and administrative (SG&A) expenses were$200.8 millionin2019, compared to$177.3 millionin2018.•GAAP net loss was$11.0 million, or$0.27per share (basic and diluted) in2019, compared to a GAAP net loss of$0.5 million, or$0.01per share (basic and diluted) in2018.•Non-GAAP net income was$70.7 million, or$1.70per share (basic) and$1.67per share (diluted), in2019, compared to non-GAAP net income of$43.5 million, or$1.06per share (basic) and$1.04per share (diluted), in2018.•Pacira ended2019with cash, cash equivalents, short-term and long-term investments (“cash”) of$356.7 million. Cash provided by operations was$70.5 millionin2019, compared to$48.9 millionin2018.•Pacira had41.5 millionbasic weighted average shares of common stock outstanding in2019.•For non-GAAP measures, Pacira had42.4 milliondiluted weighted average shares of common stock outstanding in2019.

2020Outlook

Pacira announces its full-year2020financial guidance as follows. Pacira expects:•Total revenues to be between $485 million and $500 million;•EXPAREL net product sales to be between $465 million and $475 million;•iovera° net product sales to be between $15 million and $20 million;•Non-GAAP gross margins to be between 76% and 78%;•Non-GAAP research and development (R&D) expense to be between $60 million to $70 million;•Non-GAAP selling, general and administrative (SG&A) expense to be between $180 million and $190 million; and•Stock-based compensation to be between $35 million and $40 million.

See “Non-GAAP Financial Information” and “Reconciliations of GAAP to Non-GAAP2020Financial Guidance” below.

Today’s Conference Call and Webcast Reminder

The Pacira management team will host a conference call to discuss the company’s financial results and recent developments today, Thursday,February 20, 2020, at 8:30 a.m. ET. To participate in the conference call, dial 1-877-845-0779 and provide the passcode 8765839. International callers may dial 1-720-545-0035 and use the same passcode. In addition, a live audio of the conference call will be available as a webcast. Interested parties can access the event through the “Events” page on the Pacira website at investor.pacira.com.

For those unable to participate in the live call, a replay will be available at 1-855-859-2056 (domestic) or 1-404-537-3406 (international) using the passcode 8765839. The replay of the call will be available for one week from the date of the live call. The webcast will be available on the Pacira website for approximately two weeks following the call.

Non-GAAP Financial Information

This press release contains financial measures that do not comply with U.S. generally accepted accounting principles (GAAP), such as non-GAAP net income, non-GAAP net income per share, non-GAAP cost of goods sold, non-GAAP gross margins, non-GAAP research and development (R&D) expense and non-GAAP selling, general and administrative (SG&A) expense, because such measures exclude milestone revenue; acquisition-related charges, product discontinuation costs and other expense; stock-based compensation; amortization of debt discount; amortization of acquired intangible assets; an income tax benefit and step-up in basis of inventory in connection with the acquisition of MyoScience, Inc.; and loss on investment and other non-operating income.

These measures supplement Pacira’s financial results prepared in accordance with GAAP. Pacira management uses these measures to better analyze its financial results, estimate its future cost of goods sold, gross margins, R&D expense and SG&A expense outlook for2020and to help make managerial decisions. In management’s opinion, these non-GAAP measures are useful to investors and other users of our financial statements by providing greater transparency into the operating performance at Pacira and its future outlook. Such measures should not be deemed to be an alternative to GAAP requirements or a measure of liquidity for Pacira. Non-GAAP measures are also unlikely to be comparable with non-GAAP disclosures released by other companies. See the tables below for a reconciliation of GAAP to non-GAAP

measures, and a reconciliation of our GAAP to non-GAAP2020financial guidance for gross margins, R&D expense and SG&A expense.

About Pacira BioSciences

Pacira BioSciences, Inc. (Nasdaq: PCRX) is a leading provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for health care practitioners and their patients. The company’s long-acting local analgesic, EXPAREL®(bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012. EXPAREL utilizes DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. In April 2019, Pacira acquired the iovera°®system, a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.

About EXPAREL

EXPAREL (bupivacaine liposome injectable suspension) is indicated for single-dose infiltration in adults to produce postsurgical local analgesia and as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia. Safety and efficacy have not been established in other nerve blocks. The product combines bupivacaine with DepoFoam, a proven product delivery technology that delivers medication over a desired time period. EXPAREL represents the first and only multivesicular liposome local anesthetic that can be utilized in the peri- or postsurgical setting. By utilizing the DepoFoam platform, a single dose of EXPAREL delivers bupivacaine over time, providing significant reductions in cumulative pain scores with up to a 78 percent decrease in opioid consumption; the clinical benefit of the opioid reduction was not demonstrated. Additional information is available at www.EXPAREL.com.

Important Safety Information for Patients

EXPAREL should not be used in obstetrical paracervical block anesthesia. In studies where EXPAREL was injected into the wound, the most common side effects were nausea, constipation, and vomiting. In studies where EXPAREL was injected near a nerve, the most common side effects were nausea, fever, and constipation. EXPAREL is not recommended to be used in patients younger than 18 years old or in pregnant women. Tell your healthcare provider if you have liver disease, since this may affect how the active ingredient (bupivacaine) in EXPAREL is eliminated from your body. EXPAREL should not be injected into the spine, joints, or veins. The active ingredient in EXPAREL: can affect your nervous system and your cardiovascular system; may cause an allergic reaction; may cause damage if injected into your joints.

About iovera°

The iovera° system is used to destroy tissue during surgical procedures by applying freezing cold. It can also be used to produce lesions in peripheral nervous tissue by the application of cold to the selected site for the blocking of pain. It is also indicated for the relief of pain and symptoms associated with osteoarthritis of the knee for up to 90 days. In one study, the majority of the patients suffering from osteoarthritis of the knee experienced pain and system relief beyond 150 days.1The iovera° system’s “1×90” Smart Tip configuration (indicating one needle which is 90 mm long) can also facilitate target nerve location by conducting electrical nerve stimulation from a separate nerve stimulator. The iovera° system is not indicated for treatment of central nervous system tissue.

1Radnovich, R. et al. “Cryoneurolysis to treat the pain and symptoms of knee osteoarthritis: a multicenter, randomized, double-blind, sham-controlled trial.” Osteoarthritis and Cartilage (2017) p1-10.

Important Safety Information

The iovera° system is contraindicated for use in patients with the following: Cryoglobulinemia; Paroxysmal cold hemoglobinuria; cold urticaria; Raynaud’s disease; open and/or infected wounds at or near the treatment line.Potential complications: As with any surgical treatment that uses needle-based therapy, there is potential for temporary site-specific reactions, including but not limited to: bruising (ecchymosis); swelling (edema); inflammation and/or redness (erythema); pain and/or tenderness; altered sensation (localized dysesthesia). Typically, these reactions resolve with no physician intervention. Patients may help the healing process by applying ice packs to the affected sites, and by taking over-the-counter analgesics.

Forward-Looking Statements

Any statements in this press release about the company’s future expectations, plans, outlook, projections and prospects, and other statements containing the words “believes,” “anticipates,” “plans,” “estimates,” “expects,” “intends,” “may,” “will,” “would,” “could,” “can” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks relating to: the success of the company’s sales and manufacturing efforts in support of the commercialization of EXPAREL; the rate and degree of market acceptance of EXPAREL; the size and growth of the potential markets for EXPAREL and the company’s ability to serve those markets; the company’s plans to expand the use of EXPAREL to additional indications and opportunities, and the timing and success of any related clinical trials; the ability to realize anticipated benefits and synergies from the acquisition of MyoScience; the ability to successfully integrate iovera°and any other future acquisitions into the company’s existing business; the commercial success of iovera°and other factors discussed in the “Risk Factors” of the company’s most recent Annual Report on Form 10-K and in other filings that the company periodically makes with the SEC. In addition, the forward-looking statements included in this press release represent the company’s views as of the date of this press release. Important factors could cause actual results to differ materially from those indicated or implied by forward-looking statements, and as such the company anticipates that subsequent events and developments will cause its views to change. However, while the company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the company’s views as of any date subsequent to the date of this press release.

###

Investor Contact:

Susan Mesco, (973) 451-4030

susan.mesco@pacira.com

Media Contact:

Coyne Public Relations

Alyssa Schneider, (973) 588-2270

aschneider@coynepr.com

(Tables to Follow)

Pacira BioSciences, Inc.

Condensed Consolidated Balance Sheets

(in thousands)

(unaudited)

December 31,

2019December 31,

2018

ASSETS

Current assets:

Cash, cash equivalents and short-term investments$291,950$383,454

Accounts receivable, net47,53038,000

Inventories, net58,29648,569

Prepaid expenses and other current assets10,7817,946

Total current assets408,557477,969

Long-term investments64,79825,871

Fixed assets, net104,681108,670

Right-of-use assets, net38,124—

Goodwill99,54762,040

Intangible assets, net104,387—

Equity investment and other assets10,97114,803

Total assets$831,065$689,353

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:

Accounts payable$12,799$14,368

Accrued expenses70,42745,865

Lease liabilities4,935—

Convertible senior notes(1)—338

Contingent consideration18,179—

Income taxes payable1,33390

Total current liabilities107,67360,661

Convertible senior notes(2)306,045290,592

Lease liabilities40,938—

Contingent consideration19,963—

Other liabilities1,50216,874

Total stockholders’ equity354,944321,226

Total liabilities and stockholders’ equity$831,065$689,353

(1) Relates to our 3.25% convertible senior notes due 2019 that matured on February 1, 2019.

(2) Relates to our 2.375% convertible senior notes due 2022 that are not currently convertible.

Pacira BioSciences, Inc.

Consolidated Statements of Operations

(in thousands, except per share amounts)

(unaudited)

Three Months EndedYear Ended

December 31,December 31,

2019201820192018

Net product sales:

EXPAREL$116,939$94,422$407,877$331,112

Bupivacaine liposome injectable suspension1,6852933,1531,315

Total EXPAREL / bupivacaine liposome injectable

suspension net product sales118,62494,715411,030332,427

iovera°3,221—7,896—

Total net product sales121,84594,715418,926332,427

Collaborative licensing and milestone revenue———3,000

Royalty revenue5794002,1001,850

Total revenues122,42495,115421,026337,277

Operating expenses:

Cost of goods sold31,90423,979106,71286,845

Research and development19,65314,17472,11955,688

Selling, general and administrative54,22344,647200,782177,265

Amortization of acquired intangible assets1,967—5,703—

Acquisition-related charges, product discontinuation and other12,9655325,2301,564

Total operating expenses120,71282,853410,546321,362

Income from operations1,71212,26210,48015,915

Other income (expense):

Interest income1,6672,0047,3766,497

Interest expense(5,997)(5,753)(23,628)(21,949)

Other, net(923)(191)(4,976)(888)

Total other expense, net(5,253)(3,940)(21,228)(16,340)

Income (loss) before income taxes(3,541)8,322(10,748)(425)

Income tax expense(1,347)(37)(268)(46)

Net income (loss)$(4,888)$8,285$(11,016)$(471)

Net income (loss) per share:

Basic and diluted net income (loss) per common share$(0.12)$0.20$(0.27)$(0.01)

Weighted average common shares outstanding:

Basic41,78441,14841,51340,911

Diluted41,78442,21941,51340,911

Pacira BioSciences, Inc.

Reconciliation of GAAP to Non-GAAP Financial Information

(in thousands, except per share amounts)

(unaudited)

Three Months EndedYear Ended

December 31,December 31,

2019201820192018

GAAP net income (loss)$(4,888)$8,285$(11,016)$(471)

Non-GAAP adjustments:

Milestone revenue(1)———(3,000)

Acquisition-related charges, product discontinuation and other12,9655325,2301,564

Stock-based compensation9,1898,18633,65031,725

Amortization of debt discount3,5303,28613,74612,799

Amortization of acquired intangible assets1,967—5,703—

Income tax benefit in connection with acquisition——(1,828)—

Recognition of step-up basis in inventory from acquisition——220—

Loss on investment and other non-operating income, net1,023—4,981854

Total Non-GAAP adjustments28,67411,52581,70243,942

Non-GAAP net income$23,786$19,810$70,686$43,471

GAAP basic and diluted net income (loss) per common share$(0.12)$0.20$(0.27)$(0.01)

Non-GAAP basic net income per common share$0.57$0.48$1.70$1.06

Non-GAAP diluted net income per common share$0.56$0.47$1.67$1.04

Weighted average common shares outstanding - basic41,78441,14841,51340,911

Weighted average common shares outstanding - diluted42,61242,21942,37041,869

Cost of goods sold reconciliation:

GAAP cost of goods sold$31,904$23,979$106,712$86,845

Stock-based compensation(1,174)(1,047)(4,665)(4,478)

Recognition of step-up basis in inventory from acquisition——(220)—

Non-GAAP cost of goods sold$30,730$22,932$101,827$82,367

Research and development reconciliation:

GAAP research and development$19,653$14,174$72,119$55,688

Stock-based compensation(1,342)(1,164)(5,114)(3,934)

Non-GAAP research and development$18,311$13,010$67,005$51,754

Selling, general and administrative reconciliation:

GAAP selling, general and administrative$54,223$44,647$200,782$177,265

Stock-based compensation(6,672)(5,975)(23,871)(23,313)

Non-GAAP selling, general and administrative$47,551$38,672$176,911$153,952

(1) Represents a $3.0 million upfront payment earned under our agreement with Nuance Biotech Co. Ltd. for the development and commercialization of EXPAREL in China.

Pacira BioSciences, Inc.

Reconciliation of GAAP to Non-GAAP 2020 Financial Guidance

(dollars in millions)

GAAP to Non-GAAP GuidanceGAAPStock-Based CompensationNon-GAAP

Total revenues$485 to $500——

EXPAREL net product sales$465 to $475——

iovera° net product sales$15 to $20——

Gross margin75% to 77%Approx. 1%76% to 78%

Research and development expense$64 to $76$4 to $6$60 to $70

Selling, general and administrative expense$207 to $219$27 to $29$180 to $190

Stock-based compensation$35 to $40——

EX-101.SCH

pcrx-20200220.xsd

XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT

0001000 - Document - Cover Page

link:presentationLink

link:calculationLink

link:definitionLink

EX-101.CAL

pcrx-20200220_cal.xml

XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT

EX-101.DEF

pcrx-20200220_def.xml

XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT

EX-101.LAB

pcrx-20200220_lab.xml

XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT

Cover page.

Document Type

Document Period End Date

Entity Registrant Name

Entity Incorporation, State or Country Code

Entity File Number

Entity Tax Identification Number

Entity Address, Address Line One

Entity Address, City or Town

Entity Address, State or Province

Entity Address, Postal Zip Code

City Area Code

Local Phone Number

Written Communications

Soliciting Material

Pre-commencement Tender Offer

Pre-commencement Issuer Tender Offer

Entity Emerging Growth Company

Title of 12(b) Security

Trading Symbol

Security Exchange Name

Entity Central Index Key

Amendment Flag

EX-101.PRE

pcrx-20200220_pre.xml

XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT

GRAPHIC

pacirabiosciencesa03.jpg

begin 644 pacirabiosciencesa03.jpg

M_]C_X 02D9)1@ ! 0$ 8 !@ #_X0!817AI9@ 34T *@ @ ! $Q (

M 1 /E$0 $ ! 0 %$1 0 ! %$2 0 !

M !!9&]B92!);6%G95)E861Y #_VP!# (! 0(! 0(" @(" @(" P4# P,#

M P8$! ,%!P8'!P7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&

MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$!

M 0$! 0 $" P0%!@'EZ@H.$

MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#]_**** "B

MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***

M* "BBB@ HJ.ZO8;&+S)I8X8QU9V"C\S6%J'Q/TBR)"3-S51ZR/G]!_C4(\ZG

M/S7$Q_X$:O6TK.1N9C]32 Z3S%/\2_G3LUDVGW?PK13_ %;4 2YHK,NF(-4+

MB^FB^[+(O_ J .BHKDY/$]Y:MQ(&'HR@TJ_$62!OWUNCCU1MO^-.P'5T5@V?

MQ'TVX($CR6[?[:\?F,UL6>H0:A'OMYHYE]48-2 FHHHH **** "BBB@ HHHH

M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@

MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***1W$:EF(55&23VH 6@G:,

MFO.?'G[2FB>%F>WT\_VO>+QB)L0H?=^__ .W9;NZ:.U;_EV

M@^2(#W'5OQ)JN45SW3Q3\:M"\,EHUN/MUPO'EVV&P?=ONC\\^UFWYY,?4\?D*\QM>E:UGU%.PKFP^I7&J3^9-/.?]IMH_2M6U\-V-G_J[6'\5W?SHYBCD;,9-:UG;R''[M_\

MOFND2)8A\JJOT&*=4@9=K!(%^XW3TK012(VXJ2B@#-NHF/\ "WY5E7J,O52/

MJ*Z>CK0!P=[U-9=[U->E3:?;W _>0Q-]5%4+SP9I]YUA,9]48C_ZU5)+?1YM4TZ'5[N,RP6+W*+WUQ#:6ENNZ265@JH/;['IY^[:0$JA'^T>K?CQZ 5YVEQ)=W

M#2RR/))(Y9WYKN/AM\'=>^(S*VGV;+:]&NIODA7\?XOHH)J[6)N9

M=GUKJ/!_@?5O&$P73K&:X X+@;8U^K'@?G7LG@']E[1?#*QS:DS:O=+R0XVP

M*?9>_P#P(D>PKTJVMH[.!8H8XX8HQA410JJ/8"ES!RGD_A3]FAD59-7OL="8

M;8?S8_T'XUZ)X?\ &C^&%7['8PK(O\ RT(

M-$T]AU%S?10D?]],*$I2=D4HM[&W17*VOQT\$WTHCA\8^%9I#T5-6@8G\ ]=

M)8ZC;ZI;B:UGAN(FZ/$X=3^(HE3E'XD4XM;DU%%%22%%%% !1110 4444 %%

M%% !1110!#?Z;;ZI!Y=S!#<1G^&1 P_6N-\3? 72=95FLVET^8]-OSQ_]\GG

M\B*[BB@#YY\9? _7O#NZ2.W_ +0MUY\RV^8@>Z]?RR*\]OE:.3:P*LIP01TK

M[(KG?&7PLT/QW&WVZR3SSTN(OW/A?^T;HOQ",=K.PTO5&P!!,WR2G_ &&Z'Z'!^M>:_$?]

MES6-#5[C1W_M:U7)\L#;.:I;R6'LWX$=*^E/"'C32_'FB1

MZAI-Y%>6LG\2'E#_ '6'56]CS4V*N:E%%%( HHHH **** "BLZ+QAI,_B231

MH]4TY]8AC\V2Q6Y0W,:M>):-_P<7?M;PF.#_A/=-U"1B$42>&=/+N3P!\D(R36U_P ',&CKI7_!

M4?6)%7:+[P]IMQ]3L9"?_'*^&/AP=OQ"T$C_ *"-O_Z-6OWW)\JP%?+:-6I0

M@VX)MN*OMWL?HF"P>'GA83E3BWRKHNQ^C>I_\%7?^"C5_&5CT'QQ9Y[P_#%<

MC_OJU:N6U/\ X*(_\%'-4#>9-\8(U;_GC\/HX+Z,UO&OUWP

M55\$_P#!?[]K+P3>+(/BI-JT0ZP:EH]A _M7?\$O\

MX&_MFZ#-M!O+>U^*WP[T+Q%

M8YVRW_AV5]/NT7^]Y4K21R-[!HQ[BOU>_8G_ ."BOPG_ ."@/A";5/AQXDCO

MKNR0/J&CW:?9]4TS)P/-A))VD\!T+(3P&)!%?SJ_\%6/^"7GB;_@F3\;H=(O

M+I]>\%^(A)<>'-AS"6WN(3\LB_P 44B])(G'RLC9# D&OH,9P?EF9898G+?<<

ME=-7Y7Y-=.VEK=NAZ5?)&_P#!.?\ ;5=">3')&2 20/*/BM(_AVS"MB2.S*[KZ

M4#NODD0Y'(:Z0]J[,NP4\9B88:GO)V].[^2U-\-0E6JQI1W;/QD_:J_X*9:_

M\3O^"J%U^T!H%Q+M\.^(89O#*=-M]5L9>[0S1K(F1V8!@".Q!':OXX:_?G_@UQ_;$

M_P"%K?LJZ]\)=4NO,UCX9WGVG3E=OFDTR[9G '=O*N/.!/0+-$/2OU+CK(X1

MP%*O07\*T?\ MUZ+[G;[V?6<08"*P\:E-?!I\O\ A_S/U'HHHK\A/C KC?C%

M\\A'5O1!SW.!C/Q[K/B75/'WB*2^U*ZN=2U*\;_:/X8'%1_#OXQENG4_O'^['"/5F/ _F>V:]-^!?[$]]KL+#+IMFV&2P7Y;B4?

M[9_Y9CV^]_NU].^&O"^G^#M(CL-+LX+&SA^[%$NT9[D^I/7?"K

M]D32/":QW6NLNL7R_-Y6,6L9^G5_^!<>U>O0PI;Q+'&JQQH-JJHP%'H!6;XW

M\;Z/\-?!^I^(/$&I66C:'HUL]Y?7UW*(H+6%!N9W8\ "OP)_P""L_\ PW8=(QAV4_.0&,:^SDF0

MXK-*O)15HK>3V7^;[+]-3T,ORVKBI\M/;J^B/TZ_;K_X+N? O]B"[O-%DU:7

MQYXTM24?0_#S)-]ED'\-QU$[B%^6"SA! >>>0_+'$N1EF[D 99E4_OI_P3S_ .#=SX1_LFZ98ZWX_M;/

MXJ>/D"RO-J$&[2-/DX.V"U;*OM(_UDP8G&0L><5]]B,OR'(8+ZRO:U>B>OX;

M)>MWVN?25,-E^717M5SS[/\ RV2]3\J^$?\ @VK_ &JO%\"W%_H/A709)AO9=2\0PO("?7R/

M-Y_&OZ/K.SAT^TCM[>*.""%!'''&H5(U P . .PJ2O$J^(&*C[N$I0IQ[6

M;_*R_ \^?$=5:481BOZ]/R/YT=;_ .#8/]IW2K-I+=/A[J3J,B*VUYE=O8>9

M$B_F:^?_ (R_L"?M.?L%B;5->\&^/?"-C:L2^KZ/8&O

MZKJ;)&LT;*RJRL,$$9!%&'\0\>G:O",X]K-/[[M?@%/B3$)_O(J2^[^ON/Y:

MO@9_P6P_:>^ ,T(TOXL>(=9LX>#9^(676(G7^[FX#R*/]QU/O7WG^R[_ ,'8

MLRRV]C\9/AO&T9VK)J_A28J5[%C:3LE?5W_ 40_P"#?KX/_MF:

M??:UX3L[3X7_ ! =6D34-*M@FGZA)C@75JN$Y/62/:^3D[\;3^!'[7O[&7Q"

M_89^+ESX,^(NAR:3J48,MK

MR4:G5?#+U35N9?TT>QA_[.S!6Y$I=MG^&Y_5/^RO^U;X'_;/^#MEXZ^'VJ3:

MMX=OI'@666TEMI(Y4P)(V210=RDX)&5ST)KT:O&O^">/P.A_9N_8;^%?@N*

M6\NB^&[3[6@7;F[EC$URV/\ :GDE;\:]EK\>QD:4:\XT;\J;M?>U]+GQ-905

M22I[7=O0^0/^"YWQW\;?LT_\$[_$7C7X?^(+SPSXDT75--,5[;)&[!)+I(G0

MK(K*5(?D$5^,FF_\'&W[6>GZT>K

M1]=P_A:%7#-U()M2>Z79'[O?\&[/_!0+XS?MT?'#XHR_%#QO>>)K'0]'LVL[

M3[';6MO;22SR994AC09VH1DYX/TK]8J_%7_@T6TAGUSX[ZACY8X-$MP?=FOV

M/_H(K]JJ^+XQHTJ6;5*5&*C%MO%5C!+=V:QLTMN\5R&C8.K#:6\MNFJ

MU9S9:D\534E=71^0_A__ (.!?VM_#Q&WXL27BC^&[T'3)OU-OG]:[#PW_P '

M#?[8GB2?R--\26.K3+U2W\)VDS\].$BKX#K]Q?\ @TBT_P KX/?&>[V_Z[6=

M-ASZ[()S_P"SU^Q9_A@ZWLHNUNB77T

M/EJ\_P""N'_!0SQE9%;"W\:0I(.)-/\ AS"Q_ FT:N/\1?MZ_P#!0B.)KG4-

M5^-UG$.6?_A%'MD'_?-LH%?TH45^?QXOPD/AP-/[E_\ (GSDU_!O_@Z)_:(\!7T0

M\46?@GQW9?\ +5;K3387+#_9DMV5%/UC8>U?O'\DTOQ]X*\-

M^+;.1=N-2L(YI(O>.0C?&WHR,"/6OQ*_X+)?\&^O_#*?@W5/BI\&I-0U3P)I

MH\_6M N7:XO-!B[W$4A^::W7^,-EXQ\Q+KO9/>RS.LBS*:P^)PT:RJTE%O;1?FK'WQ^P1_PO?:/A?X

MTOBL4%CK-PCV%]*< )!=@*I8DX"RK&6) 4,:^T/B)\']"^)UJRZE:*+C&$NH

M?DFC_P"!=Q[-D5_'/7[I?\&X'_!6/5OC="_P%^(VJ2ZEK^C6377A/5+J7?/?

MVL0_>V4C'EY(D^=#R3&L@.!&N>'BG@J&%I/&8&_*MXO6R[I[V75/UN))=VBMK&EIDF:%/WD0_VTZ_B,CUQ7G_@?XEZS

M\+M<74-'NVMY.!)&?FBG7^ZZ]"/U'8@U]^5Y)\:?V2M%^)*37FE^7HNL-\V]

M$_T>E5^>/C_P#K_P@\2K;ZE;W&G7D1\RWG1B%DP>'C<=>W(Y'?!K

MWS]G#]MB/6);?0?&4T=O='$=OJC86.8]EE[*W^UT/?!Y)R]@OW/I*B@'(HJ2

M@K"^*'Q(TCX.?#;7_%GB"Z6RT/PSI\^J7\Y&?*@AC:1SCN=JG [GBMVORW_X

M.B_VSQ\)OV7M#^$.DW7EZU\2[D76IJC_ #PZ7;.K8/=?-N!& >C+#,IZUZ63

MY?+'8RGA8_:>ODMV_DCJP6&>(KQI+J_PZ_@?EG\%_P#@IMX@\+?\%7+7]H[6

M9)PVI^)7N]7MD8R;-+GS!):J/XA%:L$CST,49ZBOZC=+U2WUO3+>\LYXKJSO

M(EG@FB8-'*C ,K*1P00001V-?QC5_29_P;K_ +8O_#4'_!/G2= U&Z\_Q-\*

MY1X;NU9LR/9JNZREQV7R?W(SR3;.:_1O$')XK#TL715E#W'_ (?L_E%%%?DY\>%%%% !1110!_/#_P=+:=]B_X*3:7+MQ]

ML\$Z?+GUQWPZ_Y*#H/_ &$;?_T8M?I5_P '7MBL/[>'@6X YG\"

M6ZGW*ZA??XU^:OPZ_P"2@Z#_ -A&W_\ 1BU_0W#,KY/1?]T_2LK=\%#T/[)Z

M***_GD_-0HHHH ^,O^"^O[.UC^T%_P $Q?B!)-;K)JG@:)/%.FS$U?S&5_7+^W['#-^PE\:EN-I@;P)KF_=TQ_9\]?R-5^Q^'%:4L'

M5I/:,M/FO^ ?;9;>5E'JZW,6?:)?2OW$K^>/_@UE@FE_X*2:PT8;RX_ ^H&4CH%^U60&

M?^!$5_0Y7QW'E*,,WDX_:46_6UOT/%XA@HXQM=4F%%%%?&GAA7\TG_!>W]KZ

MX_;2_P""BNKZ+HO("RS7VXBRC)_O>"+5AWK

M]$X+P\,+0KYS76D$U'S?7]$O5GTF1TXT:=3'5-HJR]?ZLOF?*O[8_P"R=XF_

M8A_:'UWX:^+C:R:UH*V[R36A9K>X2:".9&C9@"RXD )QPRL.H->H?\$=/VQ/

M^&)/V_O!/BF\NOLOAO5I_P#A'_$!9ML8L;IE1I'/]V*013GU\G%?I%_P=5_L

M8_\ "2?#OP?\=-'M-UWX;D7PYXA9%R39RNSVLS=@LU^A9

M3C*>J/I?56?KU_S/[0*^8/VK?VX%T"6Z\,^

M"[A9+YBV\TUOXD

MT*W/ASQ1?E\SW#VX"1,#G(\Z#RY'8X)8N!@9SZY^S#^R'K'QSGCU"\\[2?#2

M-\UV4_>76.JP@]?0N?E'N1BOP7&8.>%KSH5=XMK[O\^A^=8BE*E4E2ENG8YG

MX6_"WQ!\:O%+66CVTEY.Z

M=5U77BOSWLJ<0GN(E_A'O]X^H'%=OX ^'FC_ P\-PZ3HEC%96C*M45*&[=C\OO

M^#AO_@K)(]2B;#9(^];P."J#[KR*T

MGS 1%?SB^&WPZUKXO?$#1?"OAO3YM5U[Q%>Q:?I]G#C?<3RL$11G@9)')( '

M)( K$K]=O^#5W]B:'QI\3/%7QTUJS$MKX1SH'ATNN5%]-&&NIE]&CMW2,=01

M=/W45^]5GA\ARINFM(+3^])Z:^KW[+R1^A5/9Y=@VX_97WL_3+_@EM_P36\+

M_P#!-C]GJV\/:?':ZCXPUA([GQ/KBI\^HW('^K0D!A;Q998TXX+,1N=B?IBB

MBOP/%8JKB:LJ]9WE)W;/SNM6G5FZDW=L****YS,**** "O)/VQOV(?AW^W=\

M-+?PO\1-&_M&SL;N.^LKJ!Q#>6$JL"3%+@E0ZC8XZ,I]0"/6Z*THUJE&:JTF

MXR6S6Z*IU)0DI0=F@ VC HHHK,D^5?\ @M[I_P#:?_!*?XT1XSMT:.7_ +XN

MH'_]EK^6FOZL/^"P%I]M_P""8?QO3^[X5NI/^^0&_I7\I]?LGAO+_8:J_O\

MZ(^VX7?^SS7G^B/V\_X-'-/\OX;_ !NNL?Z[4M)BS_N171_]GK]A*_)3_@TJ

MM-G[.OQ;N/\ GIXCM(\_[MMG_P!FK]:Z^!XQE?.*[\U_Z2CY[.W?&U/E^2"O

MB/\ X.)=*;4_^"2/Q*91DVEQI,_T U.U!_\ 0J^W*^0_^"\MI]M_X)*_&-/[

MMC8R?]\ZC:-_2O.R.5LRP[_OP_\ 2DOP=K]_?^#4/3_(_8/\=7!'_'QX[N%!]0MA8_

MXFOV'CR5LHFO./YGVG$+_P!B?JOS/U#HHHK\)/S\*AU+3;?6=.N+.\MX;JTN

MHVAG@F021S(P(964\,I!((/!!J:B@#^2_P#X*2?LV6_[(?[='Q,^'M@CQZ5H

M.LNVF(Y+-'93JMQ;*2>6*PRQJ3W()K-_8 ^+UW\!OVW/A3XLLYFA?1_%%@TQ

M4XWV[S+'.GT>%Y%/LQKZ$_X.,+ZWO/\ @K5\1%@96:WL])CFVGH_]FVYY]]I

M6OD[]G?PY<>,/V@? NDVBL]UJGB&PLX54G51TR!MK[,TO

M5;;7--@O+.XANK6Z020S1.'213R""."#7SM^TW^PQ:^,([C7/!L4-CJQS)-I

MP(2"[/2?%/V=?VHM:_9C\4RZ#KUO>R:"LQ2[L95*SZ>^?F>

M,-T/#['FG:^Q.VY]]33);0M)(RQQQ@LS,$8VSY:6:RB"W?&,JLC,\[#^$S/V%?LY_P7?_ &^M

M-_9\_P"";VI-X9U>";7/BVC>'M%EMY/F%O(I^V3@[2VZLGH!:#UK\EM+U2XT34[>\LY

MY;6\LY5G@FB8K)$ZD,K*1R"" 01W%?H&%JT\ZRCWO^7D;/REL_N>J^1])1E'

M'X+7[2L_)_\ #G]G-%>)?\$Y_P!K.W_;=_8Q\!_$:-X?[0UG3UBU>*,!1;ZA

M"3%BBBOY[/SOT _X+X?\%4[7]OOXWV/A/P3>23?"_P RR"SG&577;YO

MEDO,?\\U7]W%D9VF1N/-VK\9?L^?L_\ BS]J/XQ:%X#\$Z5-K'B3Q#12IRJ35.

M"NVTDO-['%&+E)1CNS\2?^#H/]M'_A[5>C_"72;KS-#^&%OYVHA&^2;5;E

M%=@

M$B@6+[

ML@C?:K(;B[)(^[YK'RE/0/,E?U/6]O'9V\$]6

M\G^U/#&IW&E7GDOOC,L,A1BC?Q*<95AP5(/>OZ3OVZ_VUY/$%[&(^\?E'&=WY)_\ !9/!N.!T-L^>:CP]S3V.*E@JCTJ*Z_P 2_P U

M?[D1PWC.2L\.]I;>J_S7Y(I_\&[_ ,0O#=C^W7#X#\9-))X?^(-L8K2W9]L+

M:I;@R0;SD?*\8FCP.69HEZ$U_21:VL5C:QP01QPPPJ$CC10JHH& !P !Q@5

M_&SX!\X90?PK^N+]C_P#:

M0TO]KS]F+P3\2='\M+3Q=I<5X\*-N^R3\I/ 3W,4RR1D^J&K\1,K]GB(8Z"T

MGH_5;?>OR*XEP?+56(C]K1^J_P"!^1Z11117YN?,A7\^/_!TA^T=+\3/VZ='

M\ 07!;3/AKHD:R1;LA;Z]"W$K?C +0?\!/K7]!U?R+(U_*SB_QK]7J_*7_@TS_Y-)^)W_8W)_Z1PU^K5? \

M7?\ (WK^J_)'SV=?[[4]?T05\H_\%Q8O._X)1_&=?^H1"WY7EN?Z5]75\J?\

M%OO^44_QH_[ T?\ Z505YV3_ ._T/\"=7\2>(-0M])T/0;.6_

MU"]G;;':P1(7DD8^@4$\R("Q[ U^"'_ 6C_P""Z=Y^W?:S?#?X;QZAH?PJAF5[ZXN!Y5YX

MGD1@R&1!_J[=6 98S\S,%9\$*B_09#P]BCE^6U<

M5.T5[O5_UU/C#]M/]HJ;]K7]K#X@?$>:.2!/%NM3WMM#)]^WMMVVWC;W2%8U

M)'=:^MO^#6;_P#"'_"9EUFYN&7]W-J!!%G I_OB3,WH

M!;X."RY^>M4445^)GPH4444 %>4?M+?LGZ)^T'I+3?)IOB*&/;;:@B_?QT24

M?Q)[]5[=P?5Z^>_^"IG[8\/["O[#WC;QY'-''KR6O]F^'T;!,NI7&8X" >&$

M?S3,O=(7K?"X>I7K1HTOBDTEZLTI4Y5)JG'=NQ_.W_P5D^,=]XY_:PU;PFU\

M;O1/A?+-X?LXX)_.MVNQ(/MLL8''SS(J9')$*^@K^@;_ ((V_LQ:7^R?_P $

M]/ 7AVQEM+K4M1MCK6N7%N=PEU&XPTJ,?6(!(.0#B 9 .:_"7_@B=^PRW_!0

M#]NS3;77/M62.7TR/V!\*>-?&G_

M 3K^,$NF^((9M4\)ZQ,9)#'_JKQU(T*=/ T]HJ[]>GZM^I]'?\%%_V2+7]N']C3QU\.9E

MA&H:Q8&;2)I#M%MJ$)$ML^[^%?-558CJC..]?R:ZQH]UX>U>ZT^^MYK.^L9G

MM[B"52LD,B,59&!Y# @@@]"*_LD\&^,M,^(/A>RUK1[R&_TW4(Q+!/&?E%SXPTNT\CPS\7(GUR$JN(X]04A;Z,>

MK%V2]'U6Z^:U^1MPSC.6$=5AU!8P^T7,:MB6!C_=EC+QM_LN:_KF^&'Q

M'TGXP_#?0/%F@7(O-#\3:=!JEA.!CS8)HUDC;'8E6&1V/%<7B!E?L,:L7!>[

M46O^);_>K?BYQ7ZB_\ !V1_R>+\-O\ L3?_

M &^N*_+OPGI4>N^*M-L9F=8;R[B@.SF(_%8D_E5&/_ (-+/AN)/F^+/CAD[@:?:@_G_P#6K\YEA^$Y.ZJ5%Y:_

M_(O\SYET\G>O-)?UZ&M\:?\ @ZY^$?ABRFC\"^ O&_BR^5#Y;ZBT&E6C-V^8

M-+)CU_=BOS)_X* ?\%I?C3_P4%MYM'US5+?POX)9]P\-Z'O@M9\=/M#DF2X/

M .'.P$9"*:_5;P'_ ,&KG[/GAR59-:\2?$SQ$P()CDU&VM83Z\1VX?G_ 'Z^

ME?@+_P $:OV:/VZUYFKS*W]\?:6=4;W0+CM79A^J

M6LOA+PKM>)[J )<70!!\F%?F&=5\4

MN3X8]E^K"BBBOE#QPK\8?^#J[]M/:G@WX#Z-=_>V^)_$@C;M\\=G Q!_Z[2L

MA_Z8-Z5^PGQ(^(6D_"7X>ZYXIUZ[2PT/PW83ZGJ%RW2""&-I)&_!5)QWK^5/

MQ]XG\7_\%4?^"AES>0QL?$GQ:\3I;V<3DR+IT,CK%"C$?\L[>W5 3_C.Z_-'IMLY$CJ>H$MR&!![6L9'6OJC]OK]L6XT"1

M_AUX)FFG\1:@1;ZA^.GQ8TC]A7X ^%/A

M+\.X6;7;+2K;1M(@C3S)+*W1!$L[*!\TSD?*,99R6.<8;3_8E_8I7X0PKXN\

M7*+[QMJ ,JK*WF_V6'Y;YN=TS9.Y^V2H/WBWS><9@\=C*F+E]IZ+R6B_ \G'

M8IXBO*J^K_#I^!!^Q!^PO!\&+*W\3^*H8;KQ9,N^"W.'CTE3V'9IO5APO1>[

M'8_X*@_L>P_MS_L0^./ *PQR:W<6AU#09&P/)U*W_>6^&/W0[ Q,W9)7KZ H

MK@P^(J4:T:]-^]%IKU1C1J2IS4X;IW/XP[NTFT^[EM[B*2&>%S')'(I5XV!P

M5(/((/[5?\&IG[9']H:%XV^!FK769-/)\4>'U=NL3%(KR%1

M03T8@]J_>\RP\,ZR>]/><5*/E+=+[]'\S]$Q5...P7N_:5UZ_P!:']&M/UC2KJ&_P!+U:VCO+.YA;='<0R*'1U/=64@@^AJ]7\^M-.S/SY-S(3_.O[#J_D#_:]\.2>#_VL?BAI,BE

M)-+\6ZK:,I'0QWDJ_P!*_3O#5KVM=>4?S9]5PM\=3T7ZE3]F&T6__:5^'D$G

M*3>)M-C;Z&ZC!K^P>OXZ?@5KB^&/C=X-U*1ML>GZY97+$]@EPC'^5?V+4_$N

M_M,._*7Z%<4_%3^?Z!1117Y@?)A1110 4444 %%%% !1110!\_\ _!5K_E&K

M\=/^Q*U/_P!)WK^3^OZP/^"K7_*-7XZ?]B5J?_I.]?R?U^P^&_\ NE7_ !?H

MC[7A?^#/U_0_>;_@TS_Y-)^)W_8W)_Z1PU^K5?E+_P &F?\ R:3\3O\ L;D_

M](X:_5JO@>+O^1O7]5^2/GLZ_P!]J>OZ(*^5/^"WW_**?XT?]@:/_P!*H*^J

MZ^5/^"WW_**?XT?]@:/_ -*H*\[)_P#?Z'^./_I2.7!?[Q3_ ,2_,_EJKZ6_

M8T_X*W_'+]@SP+(O&&N!8Y()0'1T,TC2M&RL&'EHPQTK[L

M_9 _X-3_ SX5O;35OC7XVF\4RQ,'?0?#P>TL7_V9+IL3.I_V%B/ ^:O+?\

M@W,_X*Y_\*U\06/[/WQ'U3'A[6)]G@W4KF3C3;N1N;!V/_+*9CF/^[(2O(D&

MS]S*^.XHX@S?!UW@U:G#[+BK7CZN]O.UK,\/-LRQM"HZ"M%=&ENOZ['-_"3X

M.^%?@-X#L?"_@OP_I/AGP_IJ[;>PTZW6"%/5B!]YCU+'+,>22>:Z2BBOS>4I

M2DY2=VSYB4FW=A1114B"BBB@ K\#?^#H[]M+_A:O[2V@_!W1[OS-%^&\ O=6

M5&^2;5+E P4]CY-N4 /4-<2J>E?MA^UA^T5H_P"R5^S=XS^)&N[6T[PCI(O^"GG_ 40T/1-8N+B\U+XB>(I

M=5\1WJ#:T=N7:YO91V4B,2; >-Q1>XK] X#P$/:U,SK_ 4D]?.VK^2_-'T?

M#^'7/+%U/A@OQ_X"_,_;7_@V\_8T_P"&:OV#;?QAJ5KY/B;XN3)KDQ9<21Z>

M@9;&,^JE&DG!]+K':ON7XJ?"G0_C/X,NM!\06:WECB6?AG1+/3=/MH;/3]/@2VMK>)=L\G?T71?):'B8K$2KU959=6?#/A77?%7_ 35^+/]DZV;C6?AOKTY:.YC

M0E4/3S5'\$RC&].C@<9PI%S_ (+B?LGV/[>'_!-[6M1\.B'5=)2.6\RW,F$'61(NXKZ^^)'PWT;XL^#KS0=>LH[[3;U=KHWWD/9U

M/56!Y!'(KY7^'>OZY_P3T^)J^$_%,\VI?"_Q#.W]F:HPRNG2,>=W9?\ ;3H?

MOK_$I6!QD\-B(8FG\46GZV_SV,\/6E1JQJQZ.Y_,'7] /_!KU^V1_P +@_9+

MUCX4ZI=>9K?PON_,L [?-+I=TS.@&>6\N?SE/95>$>E?D-_P59_9?M_V0?V^

M?B)X-TVW6W\/B_\ [4T,1_ZK[!=J+B%8S_$L8D\K/K$:V?\ @CK^V5_PP_\

MM]>"_%5Y=?9?#.KR_P#"/^(26VQBPNF56D?_ &89!%.>Y\G'>OW+B#!PS;*'

M*CJVE./K:]OFKKYGZ%F5&.,P5X=N9?UYK0_J?HHS17X ?G(4444 ?@G_ ,'9

M!_XS&^&W_8F_^WUS7YA_#L[?B!H1/_00M_\ T8M?IM_P=B3[OVV/AW'_ '?!

M"-^=_=C^E?F'X-G^S>,-)D_YYWD+?DX-?T)PJO\ A&HK^Z_S9^D91_N,/0_L

MNHH!S17\]GYN%%%% !1110 445'=W<6GVDMQ<21PP0H9)))&"I&H&2Q)X Y

MR: /R]_X.AOVU?\ A4/[+VC?"'1[OR]Z^=.(U!Z,

ML,RGK7Q+_P &^'P]L_ACXQ\:?M!:Y8+>0^"K)C)XKYC_X*J_MGR_MS_MN>-O'TOVT_X(D?\$ZKOX)?LQ^ =9\<0/]OM;8ZK8:9,ORV]SOV1/

MV5]0T[Q!$SXB;K[QUKCFYBAG7_ )!:L,#Y>BR;!?$$7E:UX2U2XTJ[ !VN\,A0NOJC8W*>ZL#

MWK]D\/,S]KA)8.6]-W7^%_Y._P!Z/M^&\5ST70>\=O1_\'\S]_\ _@VH_;+_

M .&B/V&3X$U2[,_B3X27"Z7AVW/)ILNY[-_HFV6 =%MT]:_1:OY@O\ @AA^

MV;_PQE_P4&\*WFH77V;PKXU/_",:X7;$<<=PZ^3,V>%$5PL+%CR$\P=S7]/M

M?$\:Y7]3S*4XKW:GO+U>Z^_7T:/"SW">PQ3:VEJOU_$*_EY_X+L?!Z;X,_\

M!4WXK6S1[+7Q!?Q^(+9\<2K>0I,Y'TF:5?JIK^H:OQJ_X.O?V2YK_2_A_P#&

MS3;7>MB&\*:XZKDHC,\]FYQT4,;E"Q[O&.XK?@+'*AF:IRVJ)Q^>Z_*WS+X=

MQ"IXOE?VE;Y[H_%57*,&4E64Y!':O[!?V7_BC%\;OV;/ 'C&&19H_%'AVPU3

MEOX0N;A9-*?\

MB7YG\N-?T,?\&L!S_P $WM>OZ#O\ @U4O/._X)W>*(O\

MGCX\O0?QL; U^P$+4>5N(^%E'5@

M5D&V%Y ?FAD4]QT

M96&596!5E9E(()%?LV;9;A RDED?'TG7X+BL+5P]65"LK2B[-'YY6I3I3=.:LT%%%%ZYXIU^[2PT/PW83ZGJ%R_W8((8VDD;\%4G'>JC%R?*MQI-NR/R

M _X.K/VU?L]EX/\ @/HMW\UQM\3^)!&W\ +1V=NV#W82RLI_NP-W%7?^#4?]

MD3^R_"_CSXW:I:8FU1QX7T%W7#"&,K->2+ZJTGD(&'0PR#UK\I/VG/CAXF_;

MW_;#\2>,I;6XN_$'Q"UP+I]@A\R2-798;2T3UV1B*(>NT5_4O^Q9^S5I_P"Q

M]^RIX%^&NG>4T?A32HK6XEC&%NKILR7,P'_32=Y'_P"!U^H<0)91D5++8_'4

M^+\Y?C9>:/K,R_V++X85?%+?\W^-EZ'J%%%%?EI\D%8?Q(^&^C_%KP;>:#KU

MG'>Z;?)M=#PR'LZGJK*>01T-;E% '\_7_!QG^R5XL^#6J?#S7]2W:MH.DP2^

M&;/6#%^\DM#(]Q:Q2-ZQL\ZA3T\S(X( _,2OZX/V^?V4]/\ VV/V0_'7PVOX

M[=IO$.FR+ITTP^6SOD_>6LV>HVS*A.,$KN'0FOY*_$&@WOA77K[2]2M9K+4-

M-N)+6ZMY5VR02HQ5T8=F5@01ZBOVW@#,_K& ^K2^*F[?]NO5?C=>B1]WPWBO

M:8;V3WB_P>J_5'].'_!"_P#;+_X;+_X)[^%;S4+K[1XI\%#_ (1?6]S;I))+

M=%$,S9Y)DMVA8L>K^8.QK[$K^=7_ (-JOVS?^&=?VY/^$#U2[\GPW\7(%TO#

MMA(M3BW/9O\ 5]TL ZM4?SZ_\ !U?JOVS_ (*$^$[;_GS\!V8/_ KZ_:OS

M-M9S;7,?\ CS\(Z=#],R7#_P#L]?G3

M7]%L@K8DBLMH-],!Z>4RPY'(:Z0CI7WO7\Q

MO_!=_P#;:_X;/_;[\0MIEY]I\(^ =WAG1-C9BF$+M]HN%PY3]Y_+9?-_@F>QD>#]OB4WM'5_I^)SG_!%G]DA?VR/^"B/@

M30+ZS6\\.^'[C_A)=;1TW1FULV60(X[K).8(C[2U_4J!@5^3_P#P:I?LJ_\

M"$?L[>,_BYJ%MMOO'&H#2-+D=>18VA/F.A])+AW4CUM5K]8*WXZS+ZSF3I1?

MNTUR_/=_CI\C3B#%>UQ3@MHZ?/K_ )?(****^,/#"BBB@ K\%?\ @Z&?C#I=KLTOXA6@TW5W1?E34K5 J,QZ RVWE@#O]FD/>OWJKYD_P""

MP7[(G_#:?_!/[QYX4M;7[5X@TZU_M[00J[I/MUJ#(B)_M2IYD&?2ST?H_\MS^5JOZF?^"-/[9__#[ W@

M_P 27UU]J\4:%'_PCWB(LVZ1KVV55\UC_>FB,4Q[9E([5_+-7Z5_\&R?[:7_

M H;]L>]^&>KW?D^'?BQ;K;VPD;"0:K &>W// \Q#-%@?_M5?LX:#^UU^SOXN

M^&_B9"='\6:>]F\JJ&>TDX:&X0'C?%*J2+GC&CFC)

M +1R1LDB' RKJ>*^BO\ @B+_ ,% X_V ?VT]-U#7+IK?P'XR1=#\2$D^7:QN

MX,-X1_TPDPQ."?+:8 $D5^P__!;_ /X) 6__ 4.^&\EQ%91]$L;MS]V)>!'*3A!A&(0*5_;."

M=+F%)(V62.10RLIRK \@@^E?C&I6FJ=)7

M9]H45Y_^R?X\\1?%/]F'X>^*/%D5A!XF\2>';#5=2BLHFCMX9YX$E=$5F9@%

M+XP6)XZUZ!6-2FX3__L[_ ()_1'[F?\&DM]YGP.^,5K_P \==L)[UO(/_ &2O

MUTK\;?\ @T7U97\.?':QS\T=SHDX'LRWRG_T$5^R5?!<91MG-9>:_P#24?.Y

MXK8Z?R_)!7QS_P %_=273/\ @D?\72QQYT.FPK]6U2T%?8U?"O\ P9^Q#\0;;/^I\*_

MV2_C?X@^'_C73SI_B'PY?L:C]R7X/\ R[_>?A=_P3N_

M;S\5?\$[_P!I/2?'GAUGN['(M-([87%M*,!XSDJ\4BY.V2-PR.O\+*17\>\

M\$EK.\4J-')&Q5T8;64C@@CL17W=_P $.?\ @K1=?\$]_C-_PB_BR[N)OA'X

MSND&J)R_]A71 1=0C7DX "K*J\LB@@,T:J?M>,N&?K]+ZUAU^]BO_ EV]5T^

M[M;W,\ROZQ#VU)>^OQ7^?;[C^E"BJ^DZM:Z]I=M?6-S;WEC>1+/;W$$@DBGC

M8!E=&7(92"""#@@YJQ7XB?!A7Y:_\'0_[:X^$?[,FB_!W1[SR]

M 22>@K^47_@J#^V5OM.!9?6\S

MFHOW8>ZOEO\ C?\ RSS%>VQG6OD^'?BU;G7X"JXC2_4A+Z,'NQD*3G_KZ%?T>U\(_\'$?[(O_

M TY_P $[M>R^06E('5K=*^IX/S/ZG

MFPQ4;[2T?SV_$_FZ\-^(K[PAXAL-6TNZFL=2TN

MYCN[2YA;;);S1L'1U/9E8 @^HK^M+]@3]JRQ_;8_9!\"_$JS\E)_$&G+_:,$

M?W;2^C)BNH@.H"S(^W/)7:>A%?R05^OW_!JK^VC_ ,(W\0O%WP+UB[VVOB-&

M\1^'5=N!=Q(%NX5[DR0*D@'0"UD/5J_1N/,J^LX#ZS!>]2U_[=>_W:/Y,^FX

MBP?M[6.\=?EU_S/W"HHHK\0/@S^:G_ (.-_$?_ D7_!4[Q< V?[/TVPL_

MIMA!_K7PK7]/O[0/_!"W]GW]J#XVZ]\0/&FC>)-5\0>(IEFNRNNSPP@JBH B

M(1M7"C@'UKC[S_@VS_92N8BJ>$O$=NW]Z/Q'=DC_ +ZM6;:@R3U-=!7Y/B)*564H[-O\SXZI).3:[A1116) 4444 ?)__!:3]MG_ (8:

M_8*\5:]I]Y]E\6^)%_X1WPX4;$D=W(-

M7M;"Q@DNKR^F2WMX8QEY9'(55 ]22!^-?U;?MK?\$S/A;_P4#UCP_=?$ZVU_

M5H?#$4T=A96VK2V=K&TI4R2%8R"7.Q!DGHH%>4_#K_@WT_9E^%/Q.\-^+M#\

M*ZY;:MX6U.WU:R$FNW,\)G@D66/>CL0RAU4E3P<8.1D5^B#X"AIY?\ MI,TC_5J]*HHK\_JU95)NI/5MMOU9\W.3E)RENPH

MHHK,D**** "BBB@#^5W_ (+'?LJK^Q__ ,%$?B)X9M+;[-H6I7O]O:*JKMC%

MG>9F5$']V)S)"/\ KB:^T>\FT_5]%O(K^QNHCB2VGB'

M(I_O*R@CW%?U._MG_P#!)_X+_M]?$+1_%'Q*T+4M2U;0[ Z9;R6FI2V8>#S&

MD"OY9!;:SN1SQO:O(O\ B&\_9/\ ^A+U[_PI+[_XY7Z]E_'^"AA(4\5&3FDD

M[)-.VG5K(M/5K

M^VC.18WL>8[F#GG"3*X4GEEVMT85ZY7C'[%_[!G@#]@7PGK.@?#B/7+#0=;O

M%U"73[W4Y;V""'(Y"L'B325:[TFX7/!,H ,)/]R94;V(YKT3

M_@GS_P %T_C/^P3I]GX?CNX/'?@&S 2/P_K4C'[%&,_+:W R\(]%(>,=D!.:

M_IJNK6.^MI(9HXYH9E*21NH974C!!!X((XP:^3OVCO\ @AW^S/\ M,W-Q>:I

M\-[#P]JUP2S:AX:D;292QZL8XOW+,>N7C8DU^A4>.,+BZ/U?-Z',NZ_.SLT_

M-/T/I*>?TJT/9XVG==U_ET^3/)/V6>[_8GMPYV_[4B1U]3^!_^"CWP!^(]LLNC_&CX8W6[_EFWB.UAE'UC=U<

M?B*_/3XG?\&E7@;5)9G\&_%WQ5HJMDQ1:OI4&I;?0%HV@_/%>3ZO_P &DWCJ

M&9A8?&+PG6&RJIK"JX

M^33?Z?J?KYKG[;_P7\,V+7.H?%SX96=N@R7F\3V2#]9*^;_VA_\ @X:_9C^

MUE,MEXPNO'^J1J=EEX9LVN0Q[9GDV08)[B0D>AKX4T7_ (-)?'$\ZC4?C%X4

MM8^[6VC7%PP_!G3^=>S_ I_X--/AKH,O$6W!>+2K*WTJ-SZ9?S

MVQUZ$'Z5G'+>&Z+YJN)E/RC%K]/U1$YLR/YK?-<2"I.AD]#E_O2W];7;?S?R-Y9Y1H0]G@J=

MO-_UK\V5?#'A^W\)>&M/TJT7;:Z9;1VD(]$C4(OZ 5>HHK\Y;;=V?,GP_P#\

M'%FKMI?_ 24^(T:MM-[=Z3!]1_:5LQ_]!K^9^OZ\OVNOV1_!_[;GP8N? /C

MN'4;CP[>74%W-%97;6LCO"V]!O7G&>H]J^78O^#;?]E&.+:W@[Q [?WF\27F

M?T?'Z5^C]]%Y+S/C3_@T<

MU/ROB/\ &ZSS_K]-TF;'^Y+=#_VI7[=U\X_L4?\ !*OX0_\ !/SQIKFN?#73

M];TV[\16:6-XEWJDEW$T:/O7"OG# ]\]":^CJ^7XDS*CC\PGBJ%^65M]'HDO

M/L>3FF*AB,3*M3V=M_2P5^>G_!SEJG]G_P#!+^\ASC[=XGTV#ZX,LG_LE?H7

M7D?[9_[$W@7]O7X4VG@OXA6^J76@V>IQ:LL5C>O:.\T

MW^CS[?\ ?CO%_P#9*^F4_P"#;C]E!8]I\&^(&/\ >/B2]S_Z'BO;OV'_ /@F

M7\*_^">5]XHF^&=CK.GCQ+[."/Y=,U"5L+>@#I'XZI8;"+#X]2

M;CHFDG=>=VM5MZ6/K,MX@A2H^SQ%VULUV^_H?%G_ ;R?\%DE^&][IOP"^*>

MK;= O)1#X.UF[D^73)6/&GRL?^6+L?W3'[C'9]QD\O\ 5_

MY$O7A[_\))>\?^1*^ROA%\-+?X._#?2/#%GJ6N:Q9Z+ +:"ZUB\:\O7C!.T2

M3-\TA484,V6P!DD\U\IQ+C,MQ=?ZU@5*+E\2:25^ZLWOU7S[GCYI6PM:I[7#

MW3>Z:_'>1XJ^+;R:';A&Q)#IX4&^E^AC9(/7

M_2'Q1L_%GQ,L?$6MZAIU@FFV=O%K4]K:6L2N[G9'&5PS,Y+,

M22_^"&'[._[+WQR\/\ Q"\'^&]8L_$/AF22:Q^T:S/=6ZN\3Q;F

M20G) C 'M7T/#_%&7Y9ESHQ4G5=VW96YNBWO9:=.[/2RW-L-A,,Z:3YW=

M[:7Z==CZF^&W@#3/A/\ #O0?"VBP?9='\-Z=;Z78PC_EE!!&L4:_@J@5M445

M^=RDY/F>Y\RVV[L****D HHHH *K:UHUKXBT>[T^^MXKNQOH7M[B"5=R31NI

M5D8=P02"/>K-%%[:H#^1/]N#]FZZ_9#_ &M_B!\-[D2;?"NL36UH\GWI[1CY

MEM*?=X'B?_@5/O#NJ:AXBNK.&RF>UU6>SCE6($(S

M+&1EPI"Y)Z*H[5YU_P 0WG[)_P#T)>O?^%)??_'*_8J''^7RPT:>*C)R<4I:

M*S=K/JM&?;4^(L,Z2C53;M9Z*WGU/L+X#_&G0_VC/@QX7\=^&[C[3H?BS38=

M3LV)&Y4D0-L117#_LQ_L/>%/V/_ (6Q^"O >K>+M,\,6UU+

M=6MC/JINDLC*=SI$9%9E0ON?;G&YW/5C17Y-B(T?:R]C)\MW:ZUMTOYGQU2,

M.9\CTZ7['LE%>>^,_P!K?X4_#CQ"VD>(OB;\/=!U99/*-EJ/B*SM;@/TV^7)

M(&S[8S7=:7JMKKFFP7EC"021RJ>0RL,@@^HK*5*<4I232>VA$

MHR2NT6****S)"BLG0O'FA^*-;U73-,UK2=1U+09$AU*TM;N.:?3GA4HN+M)6"BBFRRK#&SNRJB@LS,<

M=S4$CJ*\N\&_MO?!GXB?$#_A$] ^*_PYUKQ,TAA32['Q':7%W)(.J+&LA9F&

M#D*"1@YKU&M*E&I3=JD6O56*E"4=)*P4445F2%%>1^*_V_?@9X%\8R>']:^,

M7PQTK7(9/*EL;KQ-9Q30OTVNK2 HWLV#7K%K=1WUK'-#)'-#,H>.1*ZD9!

M!'!!'.16M2C4@DYQ:OM=6N5*G**O)6)***R_&?C?1?AQX:N=:\1:QI>@Z/9[

M?M%]J-TEK;0;F"+ODD(5A!IU( HJGX@\0Z?X3T.\U35;ZSTS3=/A:XNKN[F6&"VC499W=B%50 2

M22 *\WMOVZ_@C>WT=K#\9/A7-=32")(4\66#2.Y. H42Y))XQUK6G0J35X1

M;]%U*B:^U*[CM+:$L

MP50TDA"C+$ 9/)(%:5K=Q7UK'/#)'-#,@DCD1@RNI&001P01SD57*['=8TO7M)NBZPWVG7<=U;3%&*,%DC)4[65E.#P01U%

M:E*46G9[BVT8445R/Q?^/W@7]GW0XM2\=^,O"_@W3[ABD-QK6IPV,;^+OVQ_A#\/

M_$-UI&O?%3X;Z)JUBYBN+*_\2V5M<6[CJKQO(&4CT(S54Z4ZCM!-^BN$8REI

M%7/2**QO 7Q%\/\ Q5\,0ZWX7U[1O$FBW3,L-_I=['>6LI5BK!9(V920P(.#

MP016S4RBXNSW)::=F%%%>:?%#]L[X0_!'QA'X?\ &7Q0^'_A779 K#3]6U^U

ML[D*V"K-'(X90ET5#INI6^LZ=;WEG<0

MW5I=1K-!/"XDCF1@"K*PX92"""."#4U9DA1110 4444 %%%% !1162?'^@CQ

MP/#/]M:3_P )(;/^T1I/VR/[QK4444@

M"BL77?B/X=\+>)M)T74]>T73M9UXNNF6%U>Q0W6HE "XAC9@TFT$$[0<9&:F

M\9^.-%^''AJYUKQ%K&EZ#H]GM^T7VHW4=K;0;F"+ODD(5%+77O"^N:/XDT.^!:VU'2[R.\M;@ D'9+&2K8((.#P016Q4RBXNSW)::=F

M%%%%2 4444 ?C#\%_C9^S%\&/^"@'[8P_:#T/POJTM[XS$FCC5/!4OB!EC4W

M1N C);3"'+-&3N*;B >=N1]??\$,O"']G?!?XB>)?#G_ !*_A'XV\8W6K_#_

M ,/M?)=2:+IK [@CN+?S&^;[.6S'@YY8D^)?LA_M7>&?V(_V^OVOC\0]-\<

M6'_";>,X;G05L_"6I:@-52(W2N8VAA=>LB8)(#9X)%>X?\$D?A1XET_XP?M"

M?$Z7P5K/PO\ A[\5O$%E?>%?">JVWV.[B$,#IZ3C2LV[QE91T@K*S6K;O+9K2Y]!CG^ZENM(:MZ/1:)='W>NSV

M/MVBBBO@SY\^(?\ @FO$J?\ !1K]MIE559O%.A@D#D_Z#*?ZG\S7V]7Q;_P3

MGT+4-+_X*%?MG7-UI^H6MKJ'B;1)+6>>V>.*Z464JDQNP"N 1@[2<9'J,_:5

M>MG3OBO^W:?_ *;B=F._B_*/_I*"OS]\/_#_ $S_ (*0?\%9_BM!\0K.'Q%\

M.?V;K?3=*\/^&KY?-TV[U:]A>:>^G@;Y)70(\2APR[2A R*_0*O@'XEZGK'_

M 2^_P""COC[XM:EX=\0:Y\#OCK86#^(-3T73Y=0E\'ZM91F))9X8@S_ &:2

M-G8NH)WR8Q\H#:9+>]6-+^(X6AWO>-TO-QYDN^RU96!O[ZA\5M/6ZO;SM=,^!GP"@\0>(?"7BW5;27QOXYDT>ZT_2-"TNWG2>2*.2XCC,M

MT[QH%C4$':03@L5_1K2M,@T32[:SM8UAM;.)888QT1% 51^ J\R52&$HTL5

M?VJQ8KYK_P""OGPF\??'

M'_@G5\2_#'PU6ZF\4ZE91;+2VD,^%EUXP\06/B&_TBQGABN%T;3)=1N(5D?#>C^!

M? O@?P;\0_ J+-%X5U7P]#I_B+P[<1IB0IYB"21ER=TL;,23N8AB:^V*_+_]

MJ+X\?#C_ (*?_M#? U_V==/UCQ-\1?!WCBPU?5O&UMX?O-,M_#>CP;C=PW5S

M<11%]XV!8/F#$%>"VU_U KT%[[X]>+%T'5-9L7V7=CI$

M2"2]\AOX961D4'H5WK_%D?9=?)?_ 5C_9M\;_%'P?\ #OXD_"^PAUKXB_ _

MQ-%XHT[1Y9/+&O6H&VZLE;L\B!".Y",H^9EQADLJ:QD'4MUM?92L^5OI92M>

M^G[ &Z::5&DE#O&S1@3^$-2\&ZHVKPS=X@L <

MO:/:7T*S)#>0I.BS1F.1590P#*V"K8/((R#Q49A1QT&GC%+6]

MG*^O=IO?U08BGB(ZUT]>]RU7QG_PRK[,KX__

M ."]>@7_ (H_X)._%BPTNQO=2OKA-+$5M:0-/-)C5K,G"*"3@ DX' !/05>1

MNV8X=O\ GA_Z4AX#_>:?^)?FCZI\ #'@/1/^O"#_ -%K6O63X#5D\#:*K*RL

MMC "&&"#Y:]16M7FS^)G++7=UX(U:*&"",R22NUI( JJ,DDGC KYA_8R_

MX*P_!CX-_LB_"OPGX@T_X@6_B'POX2TK2M1B3P#JOA5)X5J*DWS?9=NG71GZ(44V"9;

MB!)%SMD4,,C!P?:G5\H>.?&/_!?V*SG_ ."7GC1-0ADN+%M6T(7$2-M:2,ZO

M:;U![$KD9[9J'_@FA\5-4_9]^*7B_P#9-\=7EQ/K7PSB_M'P'J-VQ+^(O"DC

M$6V&( :6UX@? PH50?+=JN_\%[="O\ Q)_P3#\;6FFV%]J5XVHZ*ZV]G;O<

M3.%U6U9L(@+'"@G@=JW/^"H?[,WB#QOX9\+?&+X9VID^,7P.O6UW0XHLJ^OV

M1&+[27*@DK<0;PH )W?*-OF,:^HP7GCOF-=_WY?^E,Y,?KB:G^)_F4_$>O6_A;P]?ZI=%EM=-MY+J8J,D(BE

MFP/H#7P#_P $I_V:/#O[^,V@Z7X\\=?$[4;RXTBVUR!+^R\)Z7!=

M2P6]G:0R QICRV;S NX[@2=Q_8^_:;_X"=0^!OQZTGQ1I7@?POJEY+X)^(%GH]QJ6D:KID\[SK%.U

MNCO#%_BMQT7Q./O:-]2DT?2X+%K]HPPC

M,OE*N\J&8 MG&X^M=97D7[*'[*/':WFER6GA&^U"*YA2

M#8SK)%$PQN]^>HS7N9 I.&(4%*3Y5I%VE\<=G9_/38]#+KN-1)-Z+9V>Z\G^

M1][?LDZS\+_$GP!T/4_@S;>&[7X>_LR_M)>%?VI_AJ?$W@^/68]'CNY++;J>D7&ES>8@4MB*9$8K\XP

MP&"A5X>*C)5I*::=WH]7\WI=]]$>?534VG?Y[_ # \CBOR?_X)_>(?

M@C^S[=^)_@Y^U5X-\-Z1\!W/M7YW_MC?\ !3W]G+]KG]FW

MQ9\.+KPWXR\9>/M:TRXMM,\"7/@C45UR'4&1E@9=T!2%TD*GS5D.W'&2-I]G

M(_:S4Z$82E&3C=PTC]"

M/#WA^Q\):!8Z3I=G;:?IFF6\=I:6MO&(X;:&-0B1HHX554 #@ 5P4445D2%?"]T/\ CHYMO^R"'_T]M7W17Q+=>&]2

M/_!PQ;ZO_9]]_9/_ HPVOVW[._V?SO[99O+\S&W?MYVYSBO7REV]M?_ )]R

M_0[,']O_ L^VJ***\@XS\V?^"S/P N_VF?V\/V">BZE>:'XNFT+Q7J7A;

M5+>?R3INL64%I>6H[.-I1?FJLN:+]4KKS275GTE&4J%.6ZLT_\ M]W7S2^]

M>9^KFD?\@JU_ZY)_(58JOI0VZ7;9X_=+P?H*L5\&SY\\"_X*A_M2ZA^QA^P7

M\1_B)H_EC7-%T](-+9T#K%=W,T=M#(5((8(\ROM/!"8/!KE/V*_^"7WPP^#/

MP9TFZ\5>$M!\??$;Q!9QW_BKQ1XDLH]6U'5K^90\Y\V)].VV-Q-GRH+N&1)[=GP"=GG11[L G;

MG&37S7\"?^"S'A7X ?#/2/!?[3.E^+?A'\3O#-M'I6H+>^'[V^L-=DB0)]KL

MY[6*5)(Y;5[_@?;?PV^%_AOX-^#[;P]X1\/Z+X7T&S:1[?3=*LH[.

MT@,CM(^R*,!5W.S,< '6C-3:J7YKZWWOUOYGGSYE)J6_4***XG]I

M'XZZ=^S+\"?%/C[5M/UC5M-\*6#W]Q::5;?:+R=5Q\L:9 SSR20JC+$@ FE3

MIRG)0@KMNR]6$8N345NSMJ*Y?X(_%BS^.WP>\+^---LM4TVP\5:9;ZK;VNI0

M>1=V\A(P:*4XN,G&6Z%*+3LSJ****D04444 %%%% !11

M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%

M !1110 4444 %%%% !1110 4444 %%%% !1110!1\2Z&OB?PYJ&FR7%W:QZA

M;26S3VLIBGA#J5+1N.5<9R&[$ U@? ?X(>&_V;/@[X=\">$;$:;X?\ 397,[

XML

R1.htm

IDEA: XBRL DOCUMENT

v3.19.3.a.u2

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Section 14a

-Number 240

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

XML

report.css

IDEA: XBRL DOCUMENT

/* Updated 2009-11-04 */

/* v2.2.0.24 */

/* DefRef Styles */

..report table.authRefData{

background-color: #def;

border: 2px solid #2F4497;

font-size: 1em;

position: absolute;

}

..report table.authRefData a {

display: block;

font-weight: bold;

}

..report table.authRefData p {

margin-top: 0px;

}

..report table.authRefData .hide {

background-color: #2F4497;

padding: 1px 3px 0px 0px;

text-align: right;

}

..report table.authRefData .hide a:hover {

background-color: #2F4497;

}

..report table.authRefData .body {

height: 150px;

overflow: auto;

width: 400px;

}

..report table.authRefData table{

font-size: 1em;

}

/* Report Styles */

..pl a, .pl a:visited {

color: black;

text-decoration: none;

}

/* table */

..report {

background-color: white;

border: 2px solid #acf;

clear: both;

color: black;

font: normal 8pt Helvetica, Arial, san-serif;

margin-bottom: 2em;

}

..report hr {

border: 1px solid #acf;

}

/* Top labels */

..report th {

background-color: #acf;

color: black;

font-weight: bold;

text-align: center;

}

..report th.void{

background-color: transparent;

color: #000000;

font: bold 10pt Helvetica, Arial, san-serif;

text-align: left;

}

..report .pl {

text-align: left;

vertical-align: top;

white-space: normal;

width: 200px;

white-space: normal; /* word-wrap: break-word; */

}

..report td.pl a.a {

cursor: pointer;

display: block;

width: 200px;

overflow: hidden;

}

..report td.pl div.a {

width: 200px;

}

..report td.pl a:hover {

background-color: #ffc;

}

/* Header rows... */

..report tr.rh {

background-color: #acf;

color: black;

font-weight: bold;

}

/* Calendars... */

..report .rc {

background-color: #f0f0f0;

}

/* Even rows... */

..report .re, .report .reu {

background-color: #def;

}

..report .reu td {

border-bottom: 1px solid black;

}

/* Odd rows... */

..report .ro, .report .rou {

background-color: white;

}

..report .rou td {

border-bottom: 1px solid black;

}

..report .rou table td, .report .reu table td {

border-bottom: 0px solid black;

}

/* styles for footnote marker */

..report .fn {

white-space: nowrap;

}

/* styles for numeric types */

..report .num, .report .nump {

text-align: right;

white-space: nowrap;

}

..report .nump {

padding-left: 2em;

}

..report .nump {

padding: 0px 0.4em 0px 2em;

}

/* styles for text types */

..report .text {

text-align: left;

white-space: normal;

}

..report .text .big {

margin-bottom: 1em;

width: 17em;

}

..report .text .more {

display: none;

}

..report .text .note {

font-style: italic;

font-weight: bold;

}

..report .text .small {

width: 10em;

}

..report sup {

font-style: italic;

}

..report .outerFootnotes {

font-size: 1em;

}

EXCEL

Financial_Report.xlsx

IDEA: XBRL DOCUMENT

begin 644 Financial_Report.xlsx

M4$L#!!0 ( *A 5% ?(\\#P !," + 7W)E;',O+G)E;'.MDD^+

MPD ,Q;]*F?L:5\'#8CUYZ6U9_ )Q)OU#.Y,A$[%^>X>];+=44/ 87O+>CT?V

M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-RGGD7E2B.5^S3%":4A+,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C

M-R."?S]PN -02P,$% @ J$!44"?HAPZ" L0 ! !D;V-0&UL38Y-"\(P$$3_2NG=;BGH06) L$?!D_>0;FP@R8;-"OGYIH(?

MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/

M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+""

MWTG] E!+ P04 " "H0%102]5QS^X K @ $0 &1O8U!R;W!S+V-O

M&ULS9+!:L,P#(9?9?B>R$G9&";-96.G%@8K;.QF9+4UBQUC:R1]^R5>

MFS*V!]C1TN]/GT -!H5]I.?8!XIL*=V,KO-)85B+(W-0 F/Y'0JIX2?FOL^

M.LW3,QX@:/S0!X):RCMPQ-IHUC #B[ 01=L85!A)(,+/GS&+L,, G7D

MR'."JJQ M//$_N/C2^";0._[J+] E!+ P04 " "H0%10F5R621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS

M[BYBZ(:(E/)X8-DOV]:[MR_>X%#BVR]*+41B1%G\@MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(

MWXV(]ZMOFCU7H5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU

M+,76>)7 \:V!T3$LV4"P9!AI@S&L%&KQMUAVC2/'K^!?FACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*

MY \FIS_I,C0'HYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_

MT=HWPJOX@L Y?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=R

MSTS0LS0[=R

M2^JVE+ZU)CA*]+',RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZ

MG=PZ.)Z8D;D*TU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCR

MHB'NH8:8S\-#AWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)2

M56 Q6\8#*Y"B?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYE

MLF4Q9Z;RWRT,"2Q;B%D2XDU=[=7G

MFYRN>B)V^I=WP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5

M' 86%S+D4.Z2D 83 >LX=SFWJXPD6L_UC6'ODR

MWSEPVSK> U[F$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\

MU*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHS

MU8NL.8T*;T'50.4_V]0-:/8--!R1!5XQF;8VH^1."CS&PO=V]R:W-H965T&UL=5;;CML@%/P5RQ^P-MBY*K'4;%6U4BM%6W7[3!(26XN-"R3>

M_GW!]KH6Y_ 2 YXY PP3L^ND>M,EYR9ZKT6C]W%I3+M-$GTN>*=GK4CMY23E&^N\^VRCU,W(R[XV;@2S#X>_)D+X2K9>?P9B\:3IB/.VQ_5

MO_2+MXLY,=P#A3X#Z"":G@F2+9IS#7F7^2,4S@

M)-/ 5QOF.O-/,H8)[1B>?8I\W?V3CRP/\8Q;-/8:YS_XPA&.!^,KM3N3OK

M#Z9N5:.CDS3V>M9?HJY2&F[KI4\VY:6])D\=P:_&-5>VK8:[XM QLAWOP&ULA51=C]HP$'R^_HH5ZD,K 3'?1\4AT1"J]*Y "=)5?3.)2:PF

M=FH['/GWW0"]2ICT'J+$V?5X9G;7$ZT-%(+_+I@K"V$>&OUN XY9*O1#(S$F

M_^0X.DQ81G5;YDQ@9"]51@TN5>SH7#$:Z80QDZ5.EY"ADU$N&M.)YM.)F;KR

MP!2L:DF86R'KF^IL9?/97@>M[

M2]JWD

M@8O08K?\^A;$6FI#4_C)\YM5(B,RZ%M=?4+ @;FY93SJ7?]ZDB&>L4ZDJ*ML

M=]#'RMJ%?5;IY;1BK1"1

M&5IWGD4F(AS8U7YO4[22?:T+3/[?GHO;7L947!'YHN2+22HUM\J[Y09;7^ZA

MT_VP^P@!"PN4;Z557F!G!T:&OYIXN2@XT+1@\)ZT<4 @1S(ZHZB4PJ+[Z-)1WADEAJ"G'OC

MX7W':K,9NAR=G%ZD-/X7=?"JG_X!4$L#!!0 ( *A 5%"ZH3F*UP$ #(&

M - >&POC"@J"RL.?!

MU[2=MH'<3*?'=G^]2=/;T0?QX(.^-#/?3+[YGTP!07FA:9'M23PIY49M"8

MTQ-E1=88O2-W- (^E2L@%RYS^LBE*)V8BF0TR0@_6L,

M)]$+*A<>);1Q 62Q0OR62_I/@=7KO2NDW 2F- )%9CDB./WDG3EY!G\)D<4^

M3]8K;!V?DO2>[A/FP1S'A13MK_Z_

MO,M_HI@MW7-HT:L&W5!2#D*BT(O&3M0U1'GAA_GUM#P0>)S6/$HQ:#>S@7WOT3Q U!+ P04

M " "H0%10+6VE:#H! G @ #P 'AL+W=O?GE]F)

M^+ C.F1?UCA?JE:DF^:YKUJPVM]1!RY4&F*K):2\SWW'H&O? H@U^;@H)KG5

MZ-1\-G"M.;]-2* 2)!? "&P13OY:CVFF0\,1/O6N5(7*="_TA$: EUK@F:GO

MT.U+-5)9@^QE$W>G3HL.+9ZA3IEOZ?1"C&=RHLVF8C(F3<5"&@H;_"^R!1:L

M_C2*WGWHH+54DR(0'M'C#@W*=ZG2VX *5^0W9R0?AG@Q&UL

M+G)E;'.MDD$*@S 0 +\B>4!7;>FAJ*=>O+;]0-#5B)J$[);J[YMZ44&A!R\)

M8,0)(\L)/LX'LQYT4,CQT>7S%1]_276

M@C"MA[_)1/TUP.K795]02P,$% @ J$!44 N/V ,A 0 5P0 !, !;

M0V]N=&5N=%]4>7!E&ULM51-3\,P#/TK4Z]HS># 6V[ %>8!'\@)&X;

M-5^RO=']>]QN0V(J8FC;)8GS[/=>$BOS]VT&FG3!1UH4#7-^4(I, T%3F3)$

M0:J$0;.$6*NL3:MK4'>SV;TR*3)$GG+/42SG3U#IM>?)XVZ_IUX4.F?OC&:7

MHMI$>T0ZW1.6"'[(H<9ENI&$8O+L&$)V%?UE+

M5>4,V&3604I*R@C:4@/ P9?4: 3[QNABO?>[TL@O.@BQZKSZD5!>SP=O/8P;

M&)!+*K.T!8Q)#PGPG;83UVX=\@J6$Z[];_:'29RZ!=_,W(1TKM05\-_\GR"U!+ 0(4 Q0

M ( *A 5% ?(\\#P !," + " 0 !?D !D;V-0&UL4$L! A0#% @ J$!44$O5

M% @ J$!44)E&PO=V]R:W-H965T&UL4$L! A0#

M% @ J$!44)S/?955 @ \ 4 !0 ( !RPL 'AL+W-H

M87)E9%-T&UL4$L! A0#% @ J$!44+JA.8K7 0 ,@8 T

M ( !4@X 'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL

M4$L! A0#% @ J$!44/_ )@B] A0( !H ( !NQ$

M 'AL+U]R96QS+W=O

XML

pcrx-12312019x8xk_htm.xml

IDEA: XBRL DOCUMENT

0001396814

2020-02-20

false

0001396814

8-K

2020-02-20

PACIRA BIOSCIENCES, INC.

001-35060

51-0619477

5 Sylvan Way, Suite 300

Parsippany

07054

973

254-3560

false

Common Stock, par value $0.001 per share

PCRX

NASDAQ

false

XML

FilingSummary.xml

IDEA: XBRL DOCUMENT

3.19.3.a.u2

html

false

R1.htm

0001000 - Document - Cover Page

Sheet

http://www.pacira.com/role/CoverPage

Cover Page

Cover

false

All Reports

Book

All Reports

pcrx-12312019x8xk.htm

pcrx-123119x991.htm

pcrx-20200220.xsd

pcrx-20200220_cal.xml

pcrx-20200220_def.xml

pcrx-20200220_lab.xml

pcrx-20200220_pre.xml

http://xbrl.sec.gov/dei/2019-01-31

true

XML

Show.js

IDEA: XBRL DOCUMENT

// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.

var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);

e.removeAttribute('id');a.parentNode.appendChild(e)}}

if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}

e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}

JSON

MetaLinks.json

IDEA: XBRL DOCUMENT

{

"instance": {

"pcrx-12312019x8xk.htm": {

"axisCustom": 0,

"axisStandard": 0,

"contextCount": 1,

"dts": {

"calculationLink": {

"local": [

"pcrx-20200220_cal.xml"

]

"definitionLink": {

"local": [

"pcrx-20200220_def.xml"

"remote": [

"http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",

"http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"

]

"inline": {

"local": [

"pcrx-12312019x8xk.htm"

]

"labelLink": {

"local": [

"pcrx-20200220_lab.xml"

"remote": [

"https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"

]

"presentationLink": {

"local": [

"pcrx-20200220_pre.xml"

]

"referenceLink": {

"remote": [

"https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"

]

"schema": {

"local": [

"pcrx-20200220.xsd"

"remote": [

"http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",

"http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",

"http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",

"http://www.xbrl.org/2003/xl-2003-12-31.xsd",

"http://www.xbrl.org/2003/xlink-2003-12-31.xsd",

"http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",

"http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",

"http://www.xbrl.org/2006/ref-2006-02-27.xsd",

"http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",

"http://www.xbrl.org/2005/xbrldt-2005.xsd",

"http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",

"http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",

"http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",

"https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",

"http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",

"http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",

"http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",

"http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",

"https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd",

"https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",

"https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd",

"http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd",

"http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",

"http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",

"https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",

"http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"

]

}

"elementCount": 23,

"entityCount": 1,

"hidden": {

"http://xbrl.sec.gov/dei/2019-01-31": 2,

"total": 2

"keyCustom": 0,

"keyStandard": 95,

"memberCustom": 0,

"memberStandard": 0,

"nsprefix": "pcrx",

"nsuri": "http://www.pacira.com/20200220",

"report": {

"R1": {

"firstAnchor": {

"ancestors": [

"span",

"div",

"body",

"html"

"baseRef": "pcrx-12312019x8xk.htm",

"contextRef": "D2020Q1SD",

"decimals": null,

"first": true,

"lang": "en-US",

"name": "dei:DocumentType",

"reportCount": 1,

"unique": true,

"unitRef": null,

"xsiNil": "false"

"groupType": "document",

"isDefault": "true",

"longName": "0001000 - Document - Cover Page",

"role": "http://www.pacira.com/role/CoverPage",

"shortName": "Cover Page",

"subGroupType": "",

"uniqueAnchor": {

"ancestors": [

"span",

"div",

"body",

"html"

"baseRef": "pcrx-12312019x8xk.htm",

"contextRef": "D2020Q1SD",

"decimals": null,

"first": true,

"lang": "en-US",

"name": "dei:DocumentType",

"reportCount": 1,

"unique": true,

"unitRef": null,

"xsiNil": "false"

}

"segmentCount": 0,

"tag": {

"dei_AmendmentFlag": {

"auth_ref": [],

"lang": {

"en-US": {

"role": {

"documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",

"label": "Amendment Flag",

"terseLabel": "Amendment Flag"

}

"localname": "AmendmentFlag",

"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",

"presentation": [

"http://www.pacira.com/role/CoverPage"

"xbrltype": "booleanItemType"

"dei_CityAreaCode": {

"auth_ref": [],

"lang": {

"en-US": {

"role": {

"documentation": "Area code of city",

"label": "City Area Code",

"terseLabel": "City Area Code"

}

"localname": "CityAreaCode",

"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",

"presentation": [

"http://www.pacira.com/role/CoverPage"

"xbrltype": "normalizedStringItemType"

"dei_CoverAbstract": {

"auth_ref": [],

"lang": {

"en-US": {

"role": {

"documentation": "Cover page.",

"label": "Cover page."

}

"localname": "CoverAbstract",

"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",

"xbrltype": "stringItemType"

"dei_DocumentPeriodEndDate": {

"auth_ref": [],

"lang": {

"en-US": {

"role": {

"documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",

"label": "Document Period End Date",

"terseLabel": "Document Period End Date"

}

"localname": "DocumentPeriodEndDate",

"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",

"presentation": [

"http://www.pacira.com/role/CoverPage"

"xbrltype": "dateItemType"

"dei_DocumentType": {

"auth_ref": [],

"lang": {

"en-US": {

"role": {

"documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",

"label": "Document Type",

"terseLabel": "Document Type"

}

"localname": "DocumentType",

"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",

"presentation": [

"http://www.pacira.com/role/CoverPage"

"xbrltype": "submissionTypeItemType"

"dei_EntityAddressAddressLine1": {

"auth_ref": [],

"lang": {

"en-US": {

"role": {

"documentation": "Address Line 1 such as Attn, Building Name, Street Name",

"label": "Entity Address, Address Line One",

"terseLabel": "Entity Address, Address Line One"

}

"localname": "EntityAddressAddressLine1",

"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",

"presentation": [

"http://www.pacira.com/role/CoverPage"

"xbrltype": "normalizedStringItemType"

"dei_EntityAddressCityOrTown": {

"auth_ref": [],

"lang": {

"en-US": {

"role": {

"documentation": "Name of the City or Town",

"label": "Entity Address, City or Town",

"terseLabel": "Entity Address, City or Town"

}

"localname": "EntityAddressCityOrTown",

"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",

"presentation": [

"http://www.pacira.com/role/CoverPage"

"xbrltype": "normalizedStringItemType"

"dei_EntityAddressPostalZipCode": {

"auth_ref": [],

"lang": {

"en-US": {

"role": {

"documentation": "Code for the postal or zip code",

"label": "Entity Address, Postal Zip Code",

"terseLabel": "Entity Address, Postal Zip Code"

}

"localname": "EntityAddressPostalZipCode",

"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",

"presentation": [

"http://www.pacira.com/role/CoverPage"

"xbrltype": "normalizedStringItemType"

"dei_EntityAddressStateOrProvince": {

"auth_ref": [],

"lang": {

"en-US": {

"role": {

"documentation": "Name of the state or province.",

"label": "Entity Address, State or Province",

"terseLabel": "Entity Address, State or Province"

}

"localname": "EntityAddressStateOrProvince",

"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",

"presentation": [

"http://www.pacira.com/role/CoverPage"

"xbrltype": "stateOrProvinceItemType"

"dei_EntityCentralIndexKey": {

"auth_ref": [

"r5"

"lang": {

"en-US": {

"role": {

"documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",

"label": "Entity Central Index Key",

"terseLabel": "Entity Central Index Key"

}

"localname": "EntityCentralIndexKey",

"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",

"presentation": [

"http://www.pacira.com/role/CoverPage"

"xbrltype": "centralIndexKeyItemType"

"dei_EntityEmergingGrowthCompany": {

"auth_ref": [

"r5"

"lang": {

"en-US": {

"role": {

"documentation": "Indicate if registrant meets the emerging growth company criteria.",

"label": "Entity Emerging Growth Company",

"terseLabel": "Entity Emerging Growth Company"

}

"localname": "EntityEmergingGrowthCompany",

"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",

"presentation": [

"http://www.pacira.com/role/CoverPage"

"xbrltype": "booleanItemType"

"dei_EntityFileNumber": {

"auth_ref": [],

"lang": {

"en-US": {

"role": {

"documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",

"label": "Entity File Number",

"terseLabel": "Entity File Number"

}

"localname": "EntityFileNumber",

"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",

"presentation": [

"http://www.pacira.com/role/CoverPage"

"xbrltype": "fileNumberItemType"

"dei_EntityIncorporationStateCountryCode": {

"auth_ref": [],

"lang": {

"en-US": {

"role": {

"documentation": "Two-character EDGAR code representing the state or country of incorporation.",

"label": "Entity Incorporation, State or Country Code",

"terseLabel": "Entity Incorporation, State or Country Code"

}

"localname": "EntityIncorporationStateCountryCode",

"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",

"presentation": [

"http://www.pacira.com/role/CoverPage"

"xbrltype": "edgarStateCountryItemType"

"dei_EntityRegistrantName": {

"auth_ref": [

"r5"

"lang": {

"en-US": {

"role": {

"documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",

"label": "Entity Registrant Name",

"terseLabel": "Entity Registrant Name"

}

"localname": "EntityRegistrantName",

"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",

"presentation": [

"http://www.pacira.com/role/CoverPage"

"xbrltype": "normalizedStringItemType"

"dei_EntityTaxIdentificationNumber": {

"auth_ref": [

"r5"

"lang": {

"en-US": {

"role": {

"documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",

"label": "Entity Tax Identification Number",

"terseLabel": "Entity Tax Identification Number"

}

"localname": "EntityTaxIdentificationNumber",

"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",

"presentation": [

"http://www.pacira.com/role/CoverPage"

"xbrltype": "employerIdItemType"

"dei_LocalPhoneNumber": {

"auth_ref": [],

"lang": {

"en-US": {

"role": {

"documentation": "Local phone number for entity.",

"label": "Local Phone Number",

"terseLabel": "Local Phone Number"

}

"localname": "LocalPhoneNumber",

"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",

"presentation": [

"http://www.pacira.com/role/CoverPage"

"xbrltype": "normalizedStringItemType"

"dei_PreCommencementIssuerTenderOffer": {

"auth_ref": [

"r2"

"lang": {

"en-US": {

"role": {

"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",

"label": "Pre-commencement Issuer Tender Offer",

"terseLabel": "Pre-commencement Issuer Tender Offer"

}

"localname": "PreCommencementIssuerTenderOffer",

"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",

"presentation": [

"http://www.pacira.com/role/CoverPage"

"xbrltype": "booleanItemType"

"dei_PreCommencementTenderOffer": {

"auth_ref": [

"r3"

"lang": {

"en-US": {

"role": {

"label": "Pre-commencement Tender Offer",

"terseLabel": "Pre-commencement Tender Offer"

}

"localname": "PreCommencementTenderOffer",

"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",

"presentation": [

"http://www.pacira.com/role/CoverPage"

"xbrltype": "booleanItemType"

"dei_Security12bTitle": {

"auth_ref": [

"r0"

"lang": {

"en-US": {

"role": {

"documentation": "Title of a 12(b) registered security.",

"label": "Title of 12(b) Security",

"terseLabel": "Title of 12(b) Security"

}

"localname": "Security12bTitle",

"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",

"presentation": [

"http://www.pacira.com/role/CoverPage"

"xbrltype": "securityTitleItemType"

"dei_SecurityExchangeName": {

"auth_ref": [

"r1"

"lang": {

"en-US": {

"role": {

"documentation": "Name of the Exchange on which a security is registered.",

"label": "Security Exchange Name",

"terseLabel": "Security Exchange Name"

}

"localname": "SecurityExchangeName",

"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",

"presentation": [

"http://www.pacira.com/role/CoverPage"

"xbrltype": "edgarExchangeCodeItemType"

"dei_SolicitingMaterial": {

"auth_ref": [

"r4"

"lang": {

"en-US": {

"role": {

"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",

"label": "Soliciting Material",

"terseLabel": "Soliciting Material"

}

"localname": "SolicitingMaterial",

"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",

"presentation": [

"http://www.pacira.com/role/CoverPage"

"xbrltype": "booleanItemType"

"dei_TradingSymbol": {

"auth_ref": [],

"lang": {

"en-US": {

"role": {

"documentation": "Trading symbol of an instrument as listed on an exchange.",

"label": "Trading Symbol",

"terseLabel": "Trading Symbol"

}

"localname": "TradingSymbol",

"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",

"presentation": [

"http://www.pacira.com/role/CoverPage"

"xbrltype": "tradingSymbolItemType"

"dei_WrittenCommunications": {

"auth_ref": [

"r6"

"lang": {

"en-US": {

"role": {

"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",

"label": "Written Communications",

"terseLabel": "Written Communications"

}

"localname": "WrittenCommunications",

"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",

"presentation": [

"http://www.pacira.com/role/CoverPage"

"xbrltype": "booleanItemType"

}

"unitCount": 0

}

"std_ref": {

"r0": {

"Name": "Exchange Act",

"Number": "240",

"Publisher": "SEC",

"Section": "12",

"Subsection": "b"

"r1": {

"Name": "Exchange Act",

"Number": "240",

"Publisher": "SEC",

"Section": "12",

"Subsection": "d1-1"

"r2": {

"Name": "Exchange Act",

"Number": "240",

"Publisher": "SEC",

"Section": "13e",

"Subsection": "4c"

"r3": {

"Name": "Exchange Act",

"Number": "240",

"Publisher": "SEC",

"Section": "14d",

"Subsection": "2b"

"r4": {

"Name": "Exchange Act",

"Number": "240",

"Publisher": "SEC",

"Section": "14a",

"Subsection": "12"

"r5": {

"Name": "Regulation 12B",

"Number": "240",

"Publisher": "SEC",

"Section": "12",

"Subsection": "b-2"

"r6": {

"Name": "Securities Act",

"Number": "230",

"Publisher": "SEC",

"Section": "425"

}

"version": "2.1"

}

ZIP

0001396814-20-000006-xbrl.zip

IDEA: XBRL DOCUMENT

begin 644 0001396814-20-000006-xbrl.zip

M4$L#!!0 ( *A 5% "-8/1F$$ \O!0 3 "TQ,C,Q,3EX.3DQ

M+FAT;>U]:7/;2++MYWM_13UU]X0< =( N,N>CJ?V,N-WW=V^DB=FYF,1*(H8

M@R@V%LGL7_\RJP"2DJ@-!*4"D)YI25P U'+RY%)966__S_O?WWW]]Y;)XN

M0O;E'[]\_O2.'75>O_YG[]WKU^^_OF=___KK9];OV@[[&O,H"=) 1CQ\_?K#

M;T?L:)ZFRY/7KZ^NKKI7O:Z,+UY_/7N-M^J_#J5,1-=/_:.?__LMOO7S?__7

MV[G@/OS^K[?_I]-A[Z67+424,B\6/!4^RY(@NF#_]$7RC3FLTUE_\YU?&--$A#\?.'[_-@&J1O7^N7\+#7^=/>3J6_^OFM'URR

M)%V%XJ]',QFEG1E?!.'JY&NP$ G[35RQ,[G@T1OU61+\*4X<>YF^P=;#E3^_

MY2SB"[@V&7ZP'??TP]BU^\[@8V]X>NJZIY->;_C>[K\;?>@=_?SV-8?_U%7%

MC^+)81")SEQ@7TXXCN[&AI$TP\/@(CH)Q4S=-%AZ_UE>'#$>IO=]

MG#\L?\[(7GY_/?1T]LF + =N_=)X\77N')4,8G/XQM_)_^\$H_

M"3"8.V!+$6-36"K9CWW78?"L$-B:78HXR1*\

M0E\OE%YE?+F,)??@0\9CP<3W)?0.U2)V$K^,?R=I+.'7AW]].0468!>QO )D

MF][K=S*:B1AU!/-X& ),?;YB/&7CDY[->'?191^^/JT7R"E+[N, =:8R3>7B

M9 RJI7@KE4OU^AYR'AY&B [UM+_\T-O,S9.518?EU/Q+(,]SN;V:]#Q

M;SSQ^1\G[,N[LW^]RA$9*[T!]N@LB(!W I#*6"19"*ID)F,&@@N_E2[Y8TN7

MS-8$#32E.!K?!6&^#'RXEV*TS0T+3NN^H(6A)=.UW_RR8D"U\8HM0)5DL;!T

M^Z\XN^R?0M&4+T)L*/03=(\>/_BEU&[.XGKLC!+A92GP^!H0 (&%A'%)YS" ,/&%9M9,;:EQ=]ZPA \_APO.4>]\L

MYLUY$(,7HK#CS0,Q PU0W%S.9H&G;WY;C+HLG\SW8H$7SV'RH&5I &.O9F4A

M,V@ MCV(%(;Y6@G!%Q>++ I28..DF*/.%,P*GT4BOA0:X($(?38-I?X8(^50"D70U(YT"%>M/PI7%KD"E17-$OJ^&,))11RX#

M">.PY- P:#N_$,HKA/OXF0>_ 4PS"7I=-5XW/;\G#D4@ 0@<9W98G@ML%),A@-]I64J$0)%[@*=8QAB@!7,%YO%DO@S7?9;R&PXKL-$5CWV%2!S<2 F)QY?*;/D3

MI"W2X[F0B,9LH=$7RVF6H(6]Q#87EA>(.8H6V#3*G&-)-D7*3)'I);)G,U">67E.D+9==#A (0=%**?0@!"^#"[$/%CB4^\1666C@BJ ?K(%*,Q@&0HTRJ&],D)5

M#^Y*F*FN(H27V10L1%Y(F '^@KCI@F,$5;EOJ")I!+Y"#5:'@R6-]9R%,)*I##

M4R_5$&(S/F0X&!9[!WWTN;[^'1 H7U,X4!%0V:]Q5U/XR^KSIPG9#L/Y.:(8

MRK;8>-[*#[_NFG]<0__O3-W

M]/.^ ""[S5TI#&OJ%_?30:S^.(]AI3Y^F/_Q6GWUVM=OZY.C1XK"E/X>)HM@TON<32TPF I$[#$

M0"G_!PP#!>0D2Y9"V02O0,MO'(:$AWN3ACWJ3@Y&&D7\ZATX!1-;[('40PK7 RW?2\)Z77=_^2J"-U-QP2,5)0.G[T_E_A4MO-8'

MK4C^2?YC]K?3TR]*>D*9[*V6JK*_P=DO

MWPR[ZX[V>_P2!"^98VCN>,J3P-/ACB#,4N&_(K$AL='A[+7H!)&'%NM>PC.R

MNR,#A,?I#BL0GEQ6M!"1P+188*Z;;!4JFWY5EN6>NL9Q2=>0Z!Q>="I7.&ZO

M.S9"@@;#YU8XATLR>K'UG)=JXXV\XQ=+@9['&Y:[$)UI+/BWCG*A3WAXQ5?)

M42U2M#%9;WLJG=XSK=6="96VQX Q70GE8H!LR?C;\E1>C%X"9G%XF-(6K[KL*R:3Q/(BY@N69$N=]H_?@!9(?+R8S=1[TQ4#[0@H

MBB]X%/RI1DJ-1)X0HB[*,UA6V) YS','C"U,OK'8$BX /NSH;&F!63Q@5^R1

M6'40K.R3$OLH4;SV "+BEA%Q(;,A2I>SA

MVDG1+-T>$/FB?\&F)0SH3\2:2M[=;&X^#KZZ6S$61W^&[MKV\ZK[KJ'OEC 78'?E8^T:>%6^SRQ

MSGG?/;4X8OQ&)^9J7Q(H"[P<49%@YB,FXR&UIS!>.@%STT2]JH5]1M[=;O

MVHOQU7Q^BD1\E6PY59F6BR!5R?J8"KB54)@W9"E$W(G%92"NQ&;9"^@S+D^&B5ZHDAW+V\1+)YB6JKI%K-33WVY?/IOW<35)'[NJ&J#2U+7!$& RJ7

MF?WH]#UX@HNIT-L/=_#IS:?I1/4-P=[5">XO@,(2;4[AAA.&F\!#T?%E@C0R

M"] +21Z1W^WJ#E9!FB7 A& 709?]')&T?G0N*0.I#$+U%:6/(*K@,D.-7#!:I%2.3>A\OX';6=G5W4Q[$)LW[3&.?]R7N=.[UG-EDUV=,*DCDWEKZ)SD7;KPU;>PA+WV@/:3WZ&=/%RC]Y

M\M.^4Z K&BBUL-]L_#@9=)UJ@+'9$RSW;)1!$!E3DC"1]Y,;>G?V^KX\7DG^

M.O%X-3S>-XG'^U4I>.)QXG&*/^W*)#KLC@_:.4'"U&1A.B\ ^/A-BVK9&1<>

M8K^S!!E

?C,=>9;-"Q@3QWXL:$[%7ZQ 5GUI^,_,?X%[2[

M^M'MNS%4I* :JZ"N5Y#9+]I<10D9BYEK4H>5%E$95["6MS>$2A\"

M]!@(64W"$$4#2>G RHN).1,3 -TOS^\' G2_.A%K)*!)(9-"?GI#\^S@.=]#./M.5>4/M:4,*CPW,":\E7/*+YR*J__0GS5!+ZJ

M6>)YGFRE&==NE743'CI0V)BC9=T,YXXIS:[*=ZMRK2M

M2DC-\'M(2(T0TIH%! ZU*;[OV)L=:BU7XSW7HS.[FYS=D=5[W/^65 01N:BZFMNT0HC264*C>@.E7DO.R_?;#B;4"W=J":0%^<79^XO7:[5.'J

M[SUMMF/PM)'C3=SZ](96O]%R5$6IRCU%U>F.*MZ@O>^^-*R_,]6 K5[8VM"$1VWSP0D>(AQ?/TAN:)3"+RQ7XAJSTC9NID68\G*,D-)A5$ER))%^ILVF,UYO8;O%S]Z;QY

MM1_[]0;#"G1HE[W##N7'W?ILNBH6X62DW*B__. ,[3=[:?HJUM^P$6;HL7T'

MI#^N9*&^@@$A3B9.+LW)^V[RKFA1?J]-WB_#)B0\[16>PVZLKBBY8\^-U89*

MU;.7P'R)!U)ATL>U[_90W=F*%]IG[MJERP?NN)N2Z]^S-)3RV^-1^AQ=7QL4

M/(ID%GF8AP'^TFR=M+L'G>Q;@'&VWD1_D04^_"D8AZ;),)17R7J;#:Y->VER

MF7SM06YYL

M&MX 4'\T( 1@![8>7H#17P313>R,AC\IS(S&

M/Q%6""N8L_O(O/N;)#1>(GYT*P?'5Y+5J;\G^?

MHIF,%ZK7^;JSZF)^P9GP)'PO#/(%7SG3^9@P/NM[O6 9M.-O^4!F*(/4U!"

M5UVS0ED[XFY?IR6@F8BR;PM[Q4//=/\74XTG*S@3PGB_BQW?I$)&-

MN2BB6L!>_$(H-9\*OF!7( ]L+J&E'$1IW0\/^P%H\8/$R\"B3'=LM-J$T6)=

MBU)U/!8>WGS+GD [%(;+8E_G69RHOTK#YZ.8QAF/5WJAW+4MMA[$I)ITC48.8K.*N'[1"_4,LR9\AWZY7^&76H\LKSN"!%@-62 6H:H@

M"-R28-8PR \S$K.-7%QA"3Z9S]HWO>+1P"> ]Y9:G6H#U/9I&J

M#;&, [C9$H->Q]CY5Q9+,G1/DUTYQM;.Q.-UCNO6Q[@W%W%V(:6?L 1&>.O#

M:P&3K?>?X!SC-Z+]G!\+0.YQY'K5X_5HBN]ZZS),$=)F)(KEB3?;I=LZ,#$<

M!].#GE]@XL%Z'S.H;XFCFVG[6&]3QB9)$(:X>/P;O>*_PZ*&YRPD,,^?O*@1

MYXMI?E^8MML?JV;%JIYCRJ.+0&N:1*0)&JC%-*7\._0X$K- [Z\&O;/L9$MD

M-LS\T;7L(M0K,E[AN]"+"/<7PT,4G%"4'RA>]R9/V\3=1]%6TN96]W'6-K5)

M=-N>0 XFJ)]JK$, WAIS2;8$&50CI5GV'H,/>$'G3P;*5)"Q7DU54X3BT-UA

M=F:)HHEKSU1^6XH%"N%[X>I/H1>+;S[/8JBW%DH'JL7D%*[>*=\WQ/I&30 %

M@4((UV]*O8ZNE,D+.D?8-AB/N0B7T(%O(A^[&,?!%UZ ]08290%N!G4]17()

M1(,VH1[@6SE)#-/_809FF3+O"W-LFQ/@4WTVN\SBK2E(4AAV;EN

M'.-K8\7#1((9%@;?E%6AGJFSAI4YHI"^'F6D12 <=7&N+'7JM1I8[3^!90W=

M$]JJ5\&&1'N]VHA1=3TWKONVYQ[=]-PI/>A9TX,JH-I-:J R"W9,-@K=G1/^

M FRT(UVM@I3J%-JM!44R !=_V!;K>0!'6W**GZ=

M"V#;.2K93$<6?54/.,UW??N7"!:XO^+UA7H*O()A1=,J4=#);^$AN^J:KG@G

MD>L@8,4@AG:D 5+W[@H_:BL.7@BW#J6GC&P>@N$;>!;+\S%*HO[FX+X%:^B>

MT/IFH_QZC_YNUKN,O/%;5(2>7QX^OLOE);>C&Q5\0HQZ#%0IY%WEQ;

M;:B%_A$%.('GJ.&3:V6CW6XQG@SF.X1&)>R]6,J/DB\:.\(83LDBL!%$$=

MX1"IKD%M?!%59IQA:2EAY?*F# =E(R]TM7X.#TR45P565"!]%34)%CH.N*GQO4XX7SMA

M.+O;^26-G3,E%,%X:B@[B!SZ9!6&J=UTJ%]E77C.&

MNZ3#M'&*7':X$[$@^WI@HV!:4Y1XL,W/3O6:+QQZ8A

M[MFXZ]:@Q/6:P_KNX(3PF0 ?")\B9C/X&CAN#)-<5>=!D

M\[AL"("/0PE>8?)/F1 ]I OLZ&R($Y)6X4

M52PP6JG7G:!QLR!.\I@/"NX"9@!N"Z:"XM[U]!9C#UV>"R TW09< @&'+]=]

M:X6)C^R@6WEMC!.1HDG29;^L\BL*>2^Z#S/&4_2"<1PT4!31(,\4S5]W>WL0

M]9DM 48]-YYW J(0X+P!ZA5Y:(L,HV79 E40&FS*HDN 2+!=P#P2]@

MHE#+P_;(CP+J*\'I916A41- 4MG,8*+!@F\8 O-'(40^4BIACH$VXU [6(V)QC

M!!%M+'/3O"K2I< ()?!&Z/$$-7P&/PA*\B#/&BPM/*

M':W6W]^ZD6:JWZQN;S*H^V*3V#L0-8#M1*R

MQ5"J@M56WX#$%D&DE2*N]ZGV3*6_VHS =?3UV']DH,HQ0&9(;XNKC-ZKW>C5&11=#

M@00/4\4]S8>;SWV^P.7N8':C_>KNNN7FLY VT7:Y"68T6>>O7$N3SR<2@+:Q

MY4'72# =P* &Q\W7E7K7NAGP[X&*0BTX7>%2Q$$I+HY4/G* UOHKY

M3C=^0F%1A2(I-"Q: ,NY6N KP)4_>;K2X@*/6%LMA1>1 QL 65]=(UOJO8

M405+9DIIJ]:@?L3&7#?<3\"D\.;6^RLRP2&O[H%ZM_%(.DB

MBV6XPK5^I$6$0\XM-]D, *(HY#J[G."2'OIR"!XTM6*X"(P[\-(L\*DR\ LZ

MX+JBO9C,^:*S%=I)<2FU6TCFP=N^

M6/!7>#[H+.2+/-J03Q%X4Q&F^AV+>(7K#_B]@I)?J]9A,CM^Y8U>T$ S=KW]

MXEA%T52DS%\EA9__"FR#U1)')UP5B2GKWF!JCPPOUYD4;#D'I0#6:Q[TQ!PP

MY3@7H1#E?:GD&,0,NKCY>J9*5-XV[C'4O^3>MZ0PO+5+F!O>^1H\FNMK,^3I;YP6SJ_5+_/H)6*$@.>AL

MHK!L4HE40/56@JE>.]FYYT#G">G:'#R7AV7(\5>>/*1"I/\1.;SR%3QU.DD^

MY3J,O=6(/)^UB-9>R=A?6^A3=$XN 2V%O9"_#[HB3\>^]9%NSHTWB\2UVQ_H

M,B,WWT;P T?>?!O ?_,MS)&^]1Z&5FZ^Z>U\DU_;/Y0 D6 H!%J%,Z+'5T>P

MTDQ[JPIG88ZSK5%$ %)HTS@:J6

MG7K*%W FDT$77V1;:89Z@P3ZF@S',-;+V'DBN5YH*53>=*53:.]IJ-KXH&^-

M3[P$#89>1["V ?"D'QE?(]HX2+XI?&H7#'E6N?*9WA^QWG1Q':UZ!__M X3$

M#)JGT8_9EO#WUAWR=?JMG-H\KJ4#\841@=R17VL>?0N=H%$$Z/)TC%N]XE/T*M4::**\0#T'^2W>[+Q&

MR01>H8Y,TO?-KB]\J/R1K56"8M$GSTU4PY1%"C[6NFTIAAEUNLG67*!&7N=$

M%PL7RNS/F[?5A5@HC<4V NT7:QQ)[HA$& #$[)5BY\*=F<>W[IXW"LL>J:Q(

MF#.5O:KLMWW*A)9?S-_%RNO$4QPYS8\YTVYU-=G$9F].K_@>)*DV2)) 6P?7

MT;P].\9V/N^XEOYBZ]MFU:_86PE4P#[J+Q74>8?\J[6"?$/X1

M^XBLY]B=_]')4L7RZBQ @R;?2+%UTWR=4YM1*C%XRY8___#NQIXP;>'?R8'Y

MF6C^'0IXO8:ZLUN7@;A2-)IW>[.1Y^:-H%$W694I-53$UZ_SO-IP^"B:1V\"

MC7'-^'=WU"H6T952V![.+06NQSK)IHGX(\-.JZUNRCJ1;CNR@QP$:

M[ARI,!=CP^]E2#9DVA>_35- JM:L%5Q(*&&K!

M!.4$'^;.@1HGE7S, XS_HA!/PT+!XJ@"$TD5HKO_@=?79%1@%MR\)?H'R084

MFS26NW&!;5"=W!K6G#SN@8O!>R^VK&,=21[>T]1WN/?C[/$G!-?Q6))RUV

M/!GU7K'^ /=0]FRS&II@0[L+;.C_W22,5=A&]07*XVGH:K).'LW)M' K,4"LD:C,<=

MUQT9)ED\*=KY?ST,DZF"8Q0)E1$_"*XZ]Z3Q<8.Q]5A/T5[==ZAH6C

M>^>R_^1V]7<3_5U[;5X4OM9T:X9AFNGYK*)=Y2%0-[4C6T[1&Z6?KL1FOU%D#=/)ZELG@C5@U2[^A:

M:)-)=VP/["&6&(.Q&0]^>C.5,2C1C@)."G^N*7%-^75X"O0WNBO1^.B

MK-J.:FKZ@8.)RKZX4;],?^;,TP&[4@8.9WX;"]NLX=W=_7'#UY3\"V8XKHV ^V

M^G>0L;A/>$NEZ>P@FO?"$XNIB/4@]1R+H0KJGH.JQ'6R)RP;ACY3*;!-

M3$>0>E[>>E;U>H#^W[50I'^^VWFDL\[FV9SJO'6.\S-)Y\OIN1\/88*]J&RZ

M$\>:#.PF6!M&">LS:PB2,8-EK#?N6?U!OPDRUC2+_GX%>*JK*B.]:6'E?

M.!]@^?;PJ'9L:S1VRJ#Z@>Z:2KVM8MA:0G)D3?JEK !#$4FV[2-^?I4I5JBH

ME)!K9E_88& ,1DTP,(P"NK'D7#-XCH"7R?XUD7JP=/,?6\.;6YGK"LVGVX!D^JB-G'56BIC+^-!.'O;'EN&52/$PEPS9Q

MGIF04@6!7,J;-9#:_B:ECU6LVJ5K)Q-KT*?(8%M8L6;H'+J6W2=#T$"V_!2E

M/+H(U!EC#3-B\>.

M;4U*1;&-T\%&(==4OJP;.OO6V.XU 9U-LQ#W3]FYCVWOG]MKZ5J]Y??\V*N]

MLM/RFZK*88]G#P2$Z_[+SV5[+G22W%9(['$^L

MWJ"49JZEY)KI']V4[;P:IHNE+Y_+XGRP.%U+!H0&@5!ADLV_=\?4R^N5!S]_

M.OWET^=/7S]].&>GO[UGYU]_?_S

MJD@ML#NT,[ U%OB#>B3.

MQ*8Z2[NLGY%M]5U*[*TYS3<5G?V!-2ZWK&L:.MMEFW]69Z!O13P:&7/K6Y->

M&7":RI!M(D(S$47YOH:L63UX/H*,5#W'-H[&B9'OU\[+QZ^QIN<8?F4" L9!

MLUW&*W!["@W"-3M/1@D>4\_30$:-M#B6,*&A;3S8T$U)DQ-:4^#Y%GEP(

MEO+OXH%5MNF

MAVL=>V0-1V7HVU06;A/9FHFIH6T-AU2[U8!XK7D16;>5$=F>/;3L?B/6;(T2

M$5-YN6;P=">V-9BX38!GTRS9EB0-V-:DU*J J2S8)K(S$U(4M,K,FP$=67C,*KJ2Q9,W0V*(>D:2;A[ZJ<8M--0LY#,$<3(IZ)T(5E*4ER6O!Q$'?FO3+ +EVZY)&

M =]4MFT:O%W'L3,1)^)E@KNU,6#KG*5OP-(N%SV3$/HIIG/%XQ1Q+?:%[

MO>/W=:V:KKBWNN)V>Z.'^^*ZNB\\%OA^D>47KK8O+-6;R5/[,KD#-8_$A0?-

M%O$V#/M/!F[_[B;D[VY>/FX4JI0>]7,>%[=9\@O1F>GF]B.P7[@4Q9[\$\MP+1.2)Q&*?(N\)F+ZWG>Z3V^GN;NW7!

MXXL@TLWC62J+-[3YJ]ZY"OQT?C*9=,?VP!Z.77_%18%IX,0[Y,Q$GQ

MQRU%?;1VY]?1&V=X=+>WKY\XZ/WTYNB6%:0_&F

M;K)ER"\%^A0_F"?L 1.:WTS-O

MV+3^6_#XSNE\T8BLJ?/Z4%R]'O/^7GAB,05;K>=8),@TX:T4]0=/CCG S#]A

M(>I@6, H5I+ZU4[]+ZEN34J?!\9M(V3*6?N;!U3Q\

M^) =HT^6.[#,M+;C-/LT^S3[[>PXS7X;DS __.O+Z=F'SW0\SDMO27&&UJ1'

ME4;-80/"_W/B?]*W^B[M\B/XMQ/^?7MDC4=E#IHB_!/^ZX__7L^Q'*=._-^R

M^.']/W_)EL$E]W@0886JI4RP4'80_4=X.HDOR1(\/;""RB[-VN'H6,/Q_GN7

M:K"_T2@AH>V[SP)N=T*UX G:C81VSW(JV+E&X"9P&PANQ^HYK3!*VACOU\45

M\J@_>\VF]UON.'),_=N8\"RZF4O0S")1SM@:NG6J$M6"D$S-,37I6Z-2W$J0

M(DC=$3EV',ONE3F;B#!%F+HK&NM:?;=.JQ$4C=WZ&2#:.?P]&I)K6>-)*VJ!$KC;!^X6<7+))618+&X%%$FZ/"X/;U<4XF2W'*"

M)\&3X$GP)'BV YX]"YSA)H"SF2'),[GB8;JJRO!\SDJ@E4%T,"I34N&AOII*

MHJWBREKBL5^., F/QN/13+RYEE,*<80H0M1=NX/&@SHAJF6QR,?L_LD-PGT7

MIY\U!>/%5[4Q!O^L)VW7RW%*5[IHE&$8=.I0?QNGBR9O/)10/E9EN6+_;U%>:X^;WE>:X

M^7UMY1RW)F"8GZX>73#Q'4O[/'PF4,/R%ZH_!H2\+).]+$(GH9/02>@D=!(Z

MZX+.9J8FWO7SG4Q2)F?L0DH_P4"=W\@R$*9,Q]1X6+(XB/'V5]VC@?T*&)Z+,(0&6>Q"1"+FH;)/N;\(HB!)=4&>1OI1@[[E

MNF4L45-)LTW$:+_?^R()8^"R(4AY=!'A..$\2D>Z]+[E>KH=C38:EML.8

MYGD8!6]32;5FX*0*= 1/@^$YL$8VK<<0.(T$9X.XLUU!Q5.T3), #=5.+$*>

M@I'JS7E\(1)K?;R+'R0>W#:(,FW18N!1IO"\5M:UV,MU*;'6A]3 E(>6OO=[M\

M,\>U2^:V&^>;&05V8PFZ7O ?#=M:YC

M]8:-T.U-B[M^BCRY$&P6RT5A@LKHT'7(RXS-2Y/2HDZNV!\_!5&*W>B!+W")Q&@G-H]2>-4.M-BP0^TA3-0X2-])..!]:D%#AO3]JG6H>V6"3V/FWFH;3%>KE+QY-2%3&5UYLF#V*53^J-I+*>\V#V>!Y;/;<1!?8(

MG,T#Y[%C6Z-^I8=Y$]L2H%]R,<<6i_fan5w m el3>4O;?\SGR9

M34.Q7X7;NP;V94O$_GB(\7D01.96 C[N6U4D2)49E">QR,NBAN(M1"=$)X]:

M'G#'^]<5?\J8&%EQG+B!N(&XX5;TS[%L9_^M"61K$)\0GQ"?'/='^^_[:R&9

MO.C26AUJUC>LWVWJ*\UQ\_M*!QWCD,S\(LU3X6/YCAY4*

MKQ3,)DEB8I

MN#[0*HJ_U])7-PK %$LT;C,R="F

MTF*;V,]82#FE*IT1I A2=T)JX)0I^T^0(DC= 2G;FCAE8HC&6UQUCPC>;XJ]

MURD0[?(;2EMIQOD-1H'75,:L&SI=RW7*G'I+Z"1TFFL[$CH)G>::HK#]E/Z3VX57J)=7^AE3&?IP

MBR_(R!.)Q3Y%7O?6#)=KI_OD=KJ[VWDF/!EY01CP-) 1DS/V

MM]/3+RR5[#<9==3?'X.(PU=X"!V8R7BAOEE1/\KA8$45KW>,T-=@(1+VF[AB

M9W+!;^G0!8\O@D@WCV>I+-[0*EF]'-W25/HSY^Z/)J6N*O=1

MNY]E5"65Y[(-1\\9B;S%,).G=FVRFPV_SF,AV*_PP3QA'X"-[@AVT;36:EK_

M+7A\YW22N+[TD9('F_?WPA.+*=A@/<<8>5U(ZYQ! >,+0

M' P:KETJ3MXD#C!CZLN5/CPD+O8Y=H5PT5QD/P2

M%92]50;CF61E[[67/3I>JM3R'I64'[T$MD>?RI_T\B*GB>[14ZJ@3J)9*]$L

M?6J*::X^7VE.6Y^7ULYQRV*]*Y3?F-CRC2V.8X/$\%\$1J@A5A"I"

M%:'J@$L^/X77T9

M2S_S4N8'B0?W#:),[Q''T[AD"@^L9;F*/&;N"\$GX? [=;@V&C:@R:>@>VX.9L.>I]+YUICQ!TU4NEB)*=A0H

M:HQ_-K&<<9E]M9PP&=:DN@JA14CC5R

MRP1@C#?&&A]H7$CH]I_K(I.^F.:!Q2Q*V^9K]*P!N

MSQ&IZ5FC/N&3\&DJ/EUK-&G$D2!M"R7>-%(YKH['PF=!E/+H(L!2USQ)1)HT

MU+]RK,EP5"/WBGQV\S%%:6J$J@.D.E@CFP[%)$RUFZE:$UZ\QS2^WZ3[I$LD

MIOP[FXI(S *LF@A0C2+A*3/O*DCGVM#3:9!M\U;*@]XX=\4H(3"5? F@!% "

M:+4%[*RQ2Q5G;/"R;:B>TB3H)582J]J#*=2EEDA#5;IYJ35#S(4ONLTP2)K7%

MIHO_;;9>LTA&';D4,4^AU?E),!:>"M,V5\6Q;)?VO;:%9FL'SP9YT@30)@*T

M;TW&E1;Y)W@2/"O[\RRJ# F-K

M."HE!0^,1KF>45#A^=BZB7!V'&M0:A,GP9G@;!ZUV .#T)<9

M[J]^?N.YNJ$I=03T8P?"9*?![5FCB(H0*0@6A@E!!J* (ZN/3E744=2MR

M2B%3 ZUXNSN@ ZC(C6VS /3+U)(G 2 !:(8 .-T1A?]) -HL ':9A&[*ZGP^

M7V)''L8+>1-[%[I[[KSMAT#PXN;7@(X6)WU%0G9@'Z>,DT]"1D)&0O9X,[+4

M4>XD9"1D)&1/\-6H/'5=%[N>LOK7L'ZWJ:\TQ\WO*\UQ\_O:RCEN473UGVI(

MAI:PU)U#4QE

MRS:1HL&@I1-2J"JVHL8#^O$5&;&$.L026[+@- @$"H(%80*

M0@6AHFZ[QBNPZ=3K*SU84QGZC+P@#'@:R.BD

M!HO4+\D$#>@?S65S^D=SV9S^M68NS73VZ?QT!KW

M!TT0L^:EOVG!NNOG>2J];YTI3P1ZYXNEB!(5)&UH!L"Q8SFC,N[-[:G;IT=T

M0D/;4U$ B':I4BH$1 )BI4#L6\-A&=5-0"0@5@S$_JC,%K0Z ;%%ZP+WVYUG

MPI,748"F)JX;)*E8=K*EVARHUMC7JEE-%#O:]D2FE39,6;*DAX&R2\KFM->J62"4AX27A)>%]4>!W;

ML<9NJ;KJ)+TDO22]+RJ]8]?JE3L4H9;":^8R$>W:-6= :! (%80*0@6A@E!!

M=1^P[L.92 2/O3GCD1!(S$C,2L\?V:>1:3JGC

M"4C,2,Q(S![;I\' &HX;<8)N5."BX]+$:F.!O%'B8%LX@@6DX0

M/$EX3W93?5CH;6

MY$#;[DEZ27I)>@\JO8.>-1FT1_R2[[G/I=-I,Q2^?BVBD]Z"Y[

MO;A,PLB]FX>1+Q[?E$/"CIX9R@,.>DDKRJ

MMI%;UU_3\38H,G5] &P5Z=?;#XADO.#A-77HV-K&443,/!&&^:=_/;*/U.MD

M"1#*7^\8F*_!0B3L-W'%SN2"W[*(%CR^""+=/)ZELGA#&UCJG:O 3^?P;>A\

MKJD\',%E(DZ*/VZQW-$ZQ+J.HX^.[@[ ZD'-U2JOGC[_EH\%*7/3ZO

MXP#%!O3. B

M"#00 @7;&YSG^+(.]5>9@OD;@U\992*AM IC.EX.%E6Y(D^G%@

MEZJM2+!H)"S^\L/8=5P#!X8081PB#$U>*MW3(K :B90M8^EG'ES/PU)JL^F@

M?VZ#<0\]-]1ZKE\J'YSFT9!Y+*^8: J-GT)3?+6#JY@ @AJ-?C*DES2+)7IXN@0+\WN7.32+-9[%T5#+XGC7++;&>3J[X]!!)K[CVF^I

M[81D4=73HKJS_>!7#?O*KQH-31\7 L3S $+C@>!@:L$UX9VIH&=H57FN9T

M/::H?GDMV72PUP?3KCW2,4-G8D@_:1Y+S6,^C32+=9Y%9ZQ5C#/92\?4W2][

M6B%%[8PVW(CN'_*EY,I;_Z

M^;_?OIZGB_#G_P]02P,$% @ J$!44 ?M:PWU& ';$ !4 !P8W)X

M+3$R,S$R,#$Y>#AX:RYH=&WM/6M7V\B2GV=^12]W[SW).=C6TY* @_6JT_>^>_DWX:S"8L

M*8B7,5JPD-Q$Q9A\"5G^E8RR=$*^I-G7Z)JV6F6GZF0Z31TAM!,MS5C:"T&6\T>5+//

M,"U@MK3O(/>^.BF!YT.C="HC=U#O=BFG6T*^"+O[# >SU 8)9EH'PS5O 8OE =UL)%A S

M*J8R 3-@V(8B]LC1-#A:D8S<0>$"#ID,W'S;"8B/U**QG$#'0&Z^$] 1UAE

M+EU_+I&3(,Y8@Z1PL*!K1--(/!="1'.!GD2) #\^4PD4\2B=)46V2336&^$P

MEG"8QNZ";EP[)$ PD-@8 (O(GUQ+J)]K7=>\2^3J2,761RQ6:BK%@V"O6S6;&6J%@V69F&PHXA*F%IO(5C2+&_1

M+,C2F DDN084= V#8)I*9BUA$JW)AP)-6V@- ,5H7E$Z72-\'WP5@\%T($'=)@

M.I)X6PYJ6%OSFJ3F>X/IEIMMH16H $*7&T:C")0$4H/6E&:"R/5>$[' "V=M

M5&&U08$.!,ZS"OZ'(@H&-

MA61./MD*SKFRWGDLH\%82 +$09Y8#D4B#-Y?'KY(8Q=)VA.*DAXFL[Q,:'GK

MP;O<9L46*UXT$V,@G5TDK=%8

M%F]T+HWB

ML-Y&0-\LD"P9 "+#(;,;0MD?35NSH+%&P\$B0SR3E&@ (':14O**TSU=J4>A>@?!0YJS

M^DQ!$HXBB8MM4U&71:(O5>9: W%H(\FP%Q )4835M 51Q!6U$A)"L-S4$^$B"YFGHY'$2")(

MDI\V6ZEZ"Y'SE]B"AF)MP^J6#R66LH0) Y@\G4I,5PD35HI+6?

M24E?I=#+ADL" I@$DRCR6H(3W86/P7US\25FRB!S2YI]4;

ME%I$_CB1Y3T2RQ@(H<8#2ZEA4!$"1.M4#';B6*OX!*_(JH

MFK4@G[B:!;A?_RU?U_7?TM*4(*U;%:9$:1UW,\W1=E.DW11A"R)K650ECJ;&

M+) EB@@2L38-9+$E0(2>4> U2I

7NL32H%N1?RVZ)0']CJ\8Q$5,3M>G!0\ZI2?8>A.-?;1, WGQT=A=$WR8AX#

MBT8P6&M$)U$\/[B,)BPGI^R&G*<3FAQR6![]'SM0E6EQ"$C6>\)ZIS&=8U;(

M]HZ/HML#G(1EY5^C,&0)_RO 3\M\L,3\MCC'0+J/>VO_HU[T]TA")S@>BPY<

MP#M$W M6\G [[J^J^F:YYNFTT=3:8QLKJS

M/D8Y77T._C%/9QG_Q&LA!Q7E."56E.-B6S9@G'+XQ>(;,,KPW2AB&>&3,6&@

MY9U\7*?%W()8]ZE$7W%:S6 416TGP!

MJ2&PG&_Q1467!1&75.O4% ILRS77VN,CR@F8=S7?\KJZ-3!5^+?KN0-UX&F&

M8KB]/HBZCERB:QUKFHM17FO,\)3P@:HI_[ROZ$?YE"8B$Q$ED+5%A:#',.O

M?-AO,6UM\A*X$0\D!'C%Z"HY"!B>"!;,4^L_I2&>U6[%;%0I]?+CH4Z13'/(6ARSH,&8D8'%<03_L*7O\SRV]NHK 8'SAV6[$-S5%5V[)TQS#_>3A,,V!]*TCCF$YS=K#X

M2YU&.##''T2D",$V(;YXDAVY7X3XOVP)K= O)U05H'9#JVN6%5% XVJB85H4

MZ>1P2(.O5QED1"'BE68'_U#X/X=KC-" J'4JUS^7 ZU]51)#*SE18VX*.(SB

M]*:R8X<5&TUH^ CB^J]_J%WE\(Z\[D:,DD'5BM3I+2>[J]

MC2YS.7T:&R/#P+8W6!-[9QRP!_]X4\XQ3.,0AOCC].32[Y.+2_?2O]@.N8VF

M[M&0N_"]/\Y/+D_\"^*>]HG_I_=?[NEO/O$^?_IT1#I^;Y1CR87H7PM\+\7? K6

MTXB[W?JX).?=L'&UH&^C#]F.83J(U9I#-A9.7,9!;6_CH ]QFTC"!N\B$SI\D5(VY0(/ZJHQO;&]#=Y.:A+@?#=\3MG$W3K"#O

M%I]]"K$[RPOB7^.=O!+,PO[

MFJVJ?:/K6J;;MQVE9_6Z"ICZ7M?O6\[].L$YNXIRK+47IP!Y+ M_YGHGYR[I

MG7R^\$[\4\^_V"4+LKD6\>7A3@(;QR']5+PZV\"NZJ8K&M8-,LOZOHN^%[%==RNV05Y

MU0:F.;"5^T(ZB&(& P]9)O6["N[CF$IW8_SR)G$_B<1U5Q+7[7=MKZ<8BJ(#

MT'#L2CKWT5&:OY[FN:2I]US -M]OS!K;;,QW?-%W5$WDJ-PPSEN?5'[\#CNH.

MQ8EUOVJ2BWE\#4V^T/D^N9A%8+MU17F\8L2WU8(>D>::8BQI[FFN;1I:OZM

MGN2IEJ.:FM6S^YHZZ)N.[DII[L%?/V>7Z4WR8(J?T2R/IM!F_N1$WM]E%T13

MG"5]+*^K#13#U_N:;2FV:?5 ,FW7,@:NYFAX4$="'^[\/V=GD!=&_/[&0[/)

M353$LLE_LRQG3T_%G8BHKH1,]S7?M6Q3]T&7+7/@6H[O U'["B3HOJM+B7B6

M CGB_XVF30GY1@HIEF(:+T6/U2W/C^SNCBJ:$9J$!$A&D&889YYE((#1E,;$

MOV7!K(BN&?D\ D_%\FUKBD^%\PX^1U6?:VOWW2Y2KM7V,3Q7MWW3L,$PF+[1

MMXV^XGB6[^@#U7%[:_4GM)YNQN@WR;5CZ4\NU>]WTGE]MG1J_IQ 6GHW39%.A8Q-%---HZ6;WQ3AM==-._X.5

M?;4C\Z]_V)IJ'>;DDL5LBD2LLHW],B8_28)XAM$B08'C5F%;M7\J['=1>_W^

M$9VGB'Z],0N^XM8TH5/POM,LPMQ]F-Z2(8-,B41\WYH,P%L3N_61C*(821KE

M!)\$34(6XHYW'DUF<4$3EL[R>$YRR 7RT9SWK#JD0U@'790 $%#;_9G!.!G8

M[_D"-DICF!S[840083Z9'[PLPCT/+S<9'F,5L:F*8D,3QB

M\_R!KG3-M8CV"RP)N(?9^BRI4K=\ZU -CV4/*7"H #EIH)T+PA23/V "],B?

M+GBZ[%B&U?6LONTZ**:]GM8U'6^"[42X:KNE"#_=W9\GGK$6

M(I5A/LL@49B*SLAR[:_"?B#7EE&^&,]7=+9K>;'(-A73,BQ5ZQIZUW[J@UMZ

MPS$KM>$$EOF@;GKW(;>8OL/%G>QZ

C"/ 9^6BO^7"Y2MASG;QM*YW

M5^=KW:[GF;U^WU![JNGB_ET/XFG?[+FNH2O>6L6B#'SFJC;DUEY:T<>H&QAP

M4:3!UWTRI1FYIO&,D?]4VHJBDBG>J1^_G:7]\4XV;BE_QDK^7+VOFFJWV[-5

MS;!,LZ\,NBA_7=OK]P%6E[_*Q5QP#R,5OC/O_,\WP?HY!HMWUQONKS*1/DA!+#XP,YR3@>W43H!4X;L;/UM[92(OP

M% 1A0+XK##2OLO2F&&,% P\;X26KD(T 27[%JMS94,Q%\GUG6Z.\\*F3=Z@W

MUB'?W5@TCOCEK"E>SL)COF491!NV-,%8HENDRT&Q)++J5QNV_8,72'PQBTH;

MMZJONK:IM,=.#U3L7RGKZFZWE/4_L#QNJ9Q_[C1 HW?.!9>B<3+

MK_E)R;KE\817*S8GHP;]WB>1V%A$]S;(Z3\U]71;.2L!NT AF[CG+H!P:&)@%RG ;\>4Z>\A8T

M"6D6YN6&?BBK!NKOZ+(:6+[*UV67

MW41IP\GH=;1>875T^Y>9K/;RUJMF6_H+?9GI<4+(:F6< ?=J(\WQ\XM[G>EG

M>:I*$J3>?7+M^[W_-LY61N&*M889HU];= 0VY8#&-W2>H["/L_7G[73#[%F&

M:UJ..C 5S7&Z7E]S;&N@JKHZ\7SS8.E2/\]XX]O*XA6_'D#(R?/"H?18P/*%;4EM7D=JJ\^#AJJ#P$@^, HJ$OU]:!8_K5*Z(

M'^%1OR2I@DT>P/*3KR4/RNU^2$)'LRR)\C%R"_/7<32,BG(JQVFK&*_R7-7C

MOV2T>%R(X)5'B)3*AG;KXS?H93T:TY6G/&M4H[RI%5>\OJQ3Z*!9V4NO ..U1SU1M74[Y?7H.^@>2(Y+/A

M7UCOXB+$"/Z88127,_&Y:4'R$J=]6$Y6+2RJKVMU>QH^0)ZW?-<7R8GI6'7@

M6GI>M2KLU%>Q3]+[!U?V<9^*3?G;/.R6ZQ,>[68%DA$T!^:NGNP)UI'(9P$D

MAA4>/[EWDCA[XK05M5WSYOS6'-J?O"[R^?>EWC?#

MSM_8Q@]P_L;957H=L=Y5.O6@3??'PJ&\H/1"]J!>TA[;CRIT?98'631%C_[2

MSE9(JB+:$\:;+T;4?ZRU?GM=\,D)L5G2 ?O7L]..6WO(L[/P#Q)4$O7

MFH8LJ-Z5.N#Y#X:0A[4"\V"P7M1C94QPN$=JO["B:KJJ.K>.H[;'Q>1!N[LT

M2V!9.3GC58CSJ@H1\IQ-\/AN16CZYAS>UOICKO4'L_^J8KQ0AOYDYG_GQ7E(

M,')&KQ@Y06D +X#OPO1I0'VR**N_)_PG-PG^YN:C/&NV;9WDD6HU

MKWR;T;%[CFYHWL#W+%-W!SW7=PS#&3B>Z]E*K__ZMAF?[X=:+DY^.W4O_SCW

M'WXU]7E+B*KV//=UZ[_441Z+^GL6957Q==L= ,%YJH#.\/@3W]'(RBTAF&'(

M2 [+ 4!:OFH_9&,:C[!ZCF/P*+5J@)L9LP3ZA+-X3NBL&*<9X!UN601^ 1S<

M"H-75 )^I/JNL;&^VU#>U92&^Y4-MSEU^[N=4WJ!$3B\MS]_12&FJ^%!U^2Y'?UOJVUD&'_E'PY^?WW

M$_?3Q4M3Z1\]'GM;WS.L[W7]2-K>\

M74I9?L3F!U$!0P>XNS*.V(BXX21*>&FT]N9^>97@@@49*R"Z>O&7^E_,ULDO

MBP_#-)P?_WK4&1>3^/C_ 5!+ P04 " "H0%10=XZXPD\# #@$0 $0

M '!C'-DS5A;;]L@%'[OKV!^)XX3=5NB)M76KE*E[J)V

M5?LV$7R2H#K@ 77S ^/GK_1VZ%C29 =?H2@+1$*(%TU/T

M%()Z06,I9NA)R!%.MX[[O+Q:+EG$P25I4S/Q.N]-N

M=SHF)9,D5_V(\9>-V.5(1BTA)R:RW?5M]X@HR,-C*I?'4B]WN!==QQST>CW?

M]:Y#5;@OT/ %_O/WNPT&P75WC.[WR#C2A-.X54YNQ#;PCD.6Q4AEU4AT5IB5'-!X_U-*W'X#/!-DE)$_4N )

MU=134E]&>4'.72L\;4A%=#61,Q]*A*NY2Z5:>Z;M"&P*IKR4'6:*P EG1:7XQY]X>6&;C@J*>$DX856_NUM=1J=EXHRI&+5U0142.L08NP#4%Z%A:ML^5

MML4:Y2QD$X@JF$\R7F('^1B0FS_L?[V]?>U6[R^2%6.;,YS&K7OY6^M(B.CS[!U!+ P04 " "H0%10:1&?:C54/L"KU?D

M:35?+/!L.I@\$/+^O"S1B^;'!I1#

T,[H!FVT.8@3(^2<

MA.)#"G48AV/++*#>BK'E-32LU)RYJ%T[UXXI[;HNZ;=&)MKL:9ZF0WK-^I4(

M%KE@)+A(EI-AEO2VPLA/J&S4_H/(!>_O^&X8Z6PT&M$8O:)6_ 3ZLAE]?RU7

M<4XBE'5,

ML"MPRTWO!_9:>9Z&<1_O0/?10H&M:%KI??1;GC/)CS+^?NGM+SRH_:^3LP#T

M#E0%5928T)M]3P>?4$L#!!0 ( *A 5%"%HD/;G0$ +H% 5 "TR,#(P,#(R,%]D968N>&ULM91=3\(P%(;O^15U7G=E$"X@@%&\(

MEO; &M9V:8N;_]ZV?"A1C"+>;/UXSWN>\TV$I1#(P/4 4>5RW!8PED+M[.TMCQ!OD)E8^X?)-G+ZT_ZJAW56;?;)7'W(+7B

M*Z&WSMJ)%MR%\^A$M ^1EX;R8U#A&\8Q0Y\Q+0?ZZ?C[Y?#,(+TJ I:5;1"7C(JUOP8T+G/\%UR6;@!RM_YK^RP6#Q

M1:!Y,Y[3,V>2BRLKJ++NB4QZC&>VVI-=O#S$MR[41:D*X)H2\

MFM!O.P:NGN[HYZ-Y/KN;KK 0WGO>2M2\TF

MWAS2*%A,Z::2Y-C3()Y^/^*O1A.8CPO@9++R:5V4VKD9NZGJIGWK0

M=X/$A3 BJ1T&H9\X4>![=C1J!AC18O#]HBW7?$IUP".9.6[2*^F@:S38>./;.^?UF]IS.CZ^8;^&?$X\ \+UBT']

M8@#1\OSXV\9\7S-A8PTFBRE.Z[,\*YP7)Y

MQ'#,^"GUKAJL8:VO0K1S,]W5L)@Y#_K6K->6;WM%=MZZA*4&E5G!5)!P//]4B,(Q='!%J!Y2_K

M)'%HI[*]+3?ZOII\D0KP6*#.)=_ODM#$&[\_7HH&$$5E4@9K$'9800W8^]

M8OXW/*%#0D0825'EU=,W>I/7EQE%]26;T9%%@L *8R=.7,OVK3@@8>NEQ,+$

M%O6%TN ]ZV*1"3R' G4J<5FH =OMBMY9R:E"$I,)4;Q%H,,36K .KPF]^,S0

MHI&5Q&DQ9N4=*YM]TXN*^XBP^Z(JGPB;T!&RH8OY;4E($,:.C9P01FU5F& L

MYPR]6OM1R%K&/T"3DJ\;L$P*ZJBR7M%D+*J9_>%5LHX667,JVDIIJYG,\'TO

MHC(TFPUOF:0DKK$TG](O][,K6HY9[Y5FLH 'HOBE")ON$#Y?F+-_]E]G@Z

MX;=5^76^>/Z[K,?'Y352'WO(QJ%#B.VERWJIX[A(S@2J5?:C!9X.K,=3E(0R

M3%%C[(.CDC[D$9J320>4K6;1!?E>-*,]CPWGF"$C+J!P,N'+:[[\ZRPO*!J%

MR$WJYSD!B6,O)3C"2=+6(BBPY.2C4F$_XEE&^J-] >IPX&LA?9>D!%%4.GWS

M4Q*./#ISPGD#R%;9Z !\+Z+1FL.&9/2)2 N&\)=?RTOV4(PP0B2U(\@-EEHV

MLOTH@JM*, Z5]"(Q_I[E4B>K-POJ;(IBD8$GJ96>N.E)10B9M;,(!W@ZI6=)

M:A0EE=,?0#WAB+(SKILU("*R42/XSE2C.(DNT>@P$=%,??D4EC1KAO<28H4>

M"3W?=EV(<6+'R[UF D,VO!.7P#:\6FVDN!O&FKG^D;WI^RXKV(5*$8C>RH1UZCH4B#"/HIFT)

M B/AQ[O2 _?T 22?G(C#VEWD_?*1Z[1)="8:/;7,^]H>&5 AV]Z]>C,

MP (1;_X?95Y5M"!L-KLOEH]RYJ,TBA+L(#?A]R!(K+=/NB?EIP4)$&9$,.;"#KLH(?K\(K0S,],+1QQ65RP:3[.

MJ[RX^3OCC9=GTY$=1''@!<0.[9#XT+-".VF+Q%8L?*V@,'3/FGA.!-I(XHY0

M(;5;$#U#DK.##!\3:MB(<7-"@=7@HZX9F1E2*N@_.2ULJA?%+-C^;5/_I=

M?KV^KM^'EB1!&D+H1]@+L(=\*PK;8E8*B:@6-$KTK >>;#!^$0TLLH$FG+@H

M=!CN%L:>\,F)0XV*B4DPHVM*63&G\_D]+5^63)T8VRYT

M$B_Q" YPZEM66S)R2* H&OE"^];-(J$9ZRA@E79/OT0U#20#LP<1;; 1TY$Z

MTGJEN>X2XKGD88(F3#!"+H1);GN+8=

M+-]A0I!C6\(703HU]O/HMN4>O;P+9

M^NQ5#^'AM6-D%AM/7TU0$=I_H>/[DM=#UM5E7DWI"'EQ2EPW\3P[)3#Q4&"O

M2D1][O7B:7;'I*/1(&CC(C8CO>B0A)''M=GSB

M^YZH ^1&[5L BS!@D4:\[R71[&[Z_JA(=KP8$!.-OC;ECBY7PW+X%E?,S707

MA/PY/GDQ;$*@RHTXAK01+-;AWT1T5.

M X) 3#3_VI0[FEX-R^&;73$WTUT0KYO[Y3?PC+\Z^=!^)E_\5R@G'_X/4$L#

M!!0 ( *A 5% OI[=W4 8 0U 5 "TR,#(P,#(R,%]P&ULW5M=4]LX%'WOK\AFGT/T8=??$81R2>.G9&-A#^

M_'0_A$1@.=!;GDR2;

M'@^_7H[XI3P]'7X\>??AK]'HN[@X&_AY?#O763F01D>EG@SNDW(V^#;1Q8_!

MC[RRAHRQ\>KIDVF1[#*TT\+Q]T]GERL_1TE6E%$6Z^')N\'@D0Z3

MI_I"WPRJUZ\7IQN3+*(X,=%1G,_'U>.QS&V0SJ-I!7 U>&;TS?%P$9NE==BN

MA1"HW/U[R[!\6.CC89',%ZF]-W[=\L_)88\(,CVMPGT67>MT$\2N+?'O*MC'G992VC'EKRO8P_X$PRFV8KU3!PNC"GE&KH^7,WEC;5_/^

MWC;[N()>ECJ;Z,EJ\Z[72/-XRYG"SKORI-#QT32_&T]T8EF K+H851##PAD7*D#PA!+G4 6 -GPE?J-)";B38V;QD.[),;;PR#9&D%''?\96+L(=\*GFM

M9H68Q UD@/LF@Q8([%0%I[94-(O'17%P9 @Q?&FF3STXE$R2I_GP[O];FH#Y^FH6NI(Q1CPJ/

M 0]2B94D-7B/!$W$X/93#'],7J>1OXJ6IQ/+0'*3//9\7B/6-""]^Z$GB,

M0,RX(R4FP=JMP'%/X71G,6W$(6TEU_,57Z?O482/ZU#!J&E0@ KZP!A

MB#TAP),KP.#$DI P+Y'J>H@C+

M0-BJZBDG"NQ!V408K-?":$;D6ZCC/"_**/TO6?RR#-DU('2$$Q %@?(PY#X*

MD "L=LBU15>31A7HM32:\-B1,*IMC!L='9#"$B\Z59**#O"@PP)PZ"@@$!W* &+X%H

M4F3"WG4G&[+74>B_F:0L=2;S^?PV6Q]R38H[$@)EWF:Q$F99--/-E4Q293ND\V#_@-!5B@8<

M $\P0AF!'A*\=@@%0#811._ZCZWQ^#;"."V*6VU^6QY;P\+ \1EV@:.((I)1

M%G@(U&$UWD0%O>M&-F2OH]!?F:CZ3EP_PZWY=6;MB$MB8.

MJ$V)A?1]=I;$)=QQ]VM8QG43;5!W[PLLLTM-6P\*@B

M'%D:;'7L"!\^[5@2-]GZ4>_:B2TPV&D^("T#)DI/;;*R_%V(9,M1;;H+ C)7";M4ZJS#5(H^D>!6S8A) S(6U!

MS!ES*+2^0UHGM)![P&D2^=YU%YM0]S/B'\9;K)W9&R?OU@^J/]4__)R\^Q]0

M2P$"% ,4 " "H0%10 C6#T9A! /+P4 $P @ $

M"TQ,C,Q,3EX.3DQ+FAT;5!+ 0(4 Q0 ( *A 5% '[6L-]1@ !VQ

M 5 " #AX:RYH=&U02P$"

M% ,4 " "H0%10=XZXPD\# #@$0 $0 @ 'Q6@ "TR,#(P,#(R,"YX"TR,#(P,#(R,%]C86PN>&UL4$L! A0#%

M @ J$!44(6B0]N= 0 N@4 !4 ( !V5\ '!CW=U & $-0 %0 @ %D:P "TR,#(P

B,#(R,%]P&UL4$L%!@ ' < SP$ .=Q $!

end8>6i_fan5w>

玩加电竞

关注

0
点赞
踩
0

收藏

觉得还不错? 一键收藏
0
评论
复制链接

分享到 QQ

分享到新浪微博

扫一扫